Understanding and targeting resistance mechanisms in NSCLC

Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes more clinically available, a greater proportion of patients with non-small-cell lung cancer (NSCLC) will be eligible for targeted therapies....

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Cancer Vol. 17; no. 11; pp. 637 - 658
Main Authors:	Rotow, Julia, Bivona, Trever G.
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 01.11.2017 Nature Publishing Group
Subjects:	631/67/1059/2326 631/67/1059/602 631/67/1612/1350 AKT protein Animals Antineoplastic Agents - pharmacology Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Drug Resistance, Neoplasm - drug effects Epidermal growth factor Epidermal growth factor receptors Genetic aspects Humans Kinases Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphoma Microbial drug resistance Mutation Non-small cell lung cancer Non-small cell lung carcinoma Protein-tyrosine kinase receptors Raf protein review-article Risk factors Signal transduction Threonine Tumor microenvironment Tumors
ISSN:	1474-175X, 1474-1768, 1474-1768
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes more clinically available, a greater proportion of patients with non-small-cell lung cancer (NSCLC) will be eligible for targeted therapies. Mechanisms of resistance to targeted therapies can be divided into 'on-target' alterations in the primary drug target and 'off-target' changes that influence downstream and parallel bypass signalling pathways. There is both signalling crosstalk and overlap among downstream and bypass signalling pathways that lead to resistance to the different targeted therapies currently in clinical use for treating NSCLC, suggesting that common themes in the development of drug resistance can be leveraged to guide further development of therapeutic agents and strategies. The upfront combination of therapies targeting both the oncogenic driver and common bypass pathways might delay the onset of disease progression in NSCLC and is the subject of ongoing clinical trials. Bidirectional signalling between tumour cells and components of the tumour microenvironment (TME) shapes both the characteristics of the TME and the propensity of a tumour cell towards therapeutic resistance. Tissue biopsy at disease progression might identify modes of therapeutic resistance to guide the rational selection of subsequent lines of therapy. Serial assessment of circulating tumour DNA might provide a complementary approach to capture heterogeneous and evolving resistance mechanisms in patients. Despite advances in targeting oncogenic driver mutations, advanced-stage non-small-cell lung cancer (NSCLC) remains largely incurable due to therapeutic resistance. This Review focuses on how understanding the mechanisms of resistance to targeted therapies in NSCLC can inform improved treatment strategies. The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumour microenvironment that promote therapeutic resistance. We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins. Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumour heterogeneity.
AbstractList	The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumour microenvironment that promote therapeutic resistance. We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins. Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumour heterogeneity. The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumour microenvironment that promote therapeutic resistance. We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins. Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumour heterogeneity.The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumour microenvironment that promote therapeutic resistance. We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins. Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumour heterogeneity. Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes more clinically available, a greater proportion of patients with non-small-cell lung cancer (NSCLC) will be eligible for targeted therapies. Mechanisms of resistance to targeted therapies can be divided into 'on-target' alterations in the primary drug target and 'off-target' changes that influence downstream and parallel bypass signalling pathways. There is both signalling crosstalk and overlap among downstream and bypass signalling pathways that lead to resistance to the different targeted therapies currently in clinical use for treating NSCLC, suggesting that common themes in the development of drug resistance can be leveraged to guide further development of therapeutic agents and strategies. The upfront combination of therapies targeting both the oncogenic driver and common bypass pathways might delay the onset of disease progression in NSCLC and is the subject of ongoing clinical trials. Bidirectional signalling between tumour cells and components of the tumour microenvironment (TME) shapes both the characteristics of the TME and the propensity of a tumour cell towards therapeutic resistance. Tissue biopsy at disease progression might identify modes of therapeutic resistance to guide the rational selection of subsequent lines of therapy. Serial assessment of circulating tumour DNA might provide a complementary approach to capture heterogeneous and evolving resistance mechanisms in patients. Despite advances in targeting oncogenic driver mutations, advanced-stage non-small-cell lung cancer (NSCLC) remains largely incurable due to therapeutic resistance. This Review focuses on how understanding the mechanisms of resistance to targeted therapies in NSCLC can inform improved treatment strategies. The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of clinically available signal transduction pathway inhibitors targeting these driver mutations, offers a tremendous opportunity to enhance patient outcomes. Despite these molecular advances, advanced-stage NSCLC remains largely incurable due to therapeutic resistance. In this Review, we discuss alterations in the targeted oncogene ('on-target' resistance) and in other downstream and parallel pathways ('off-target' resistance) leading to resistance to targeted therapies in NSCLC, and we provide an overview of the current understanding of the bidirectional interactions with the tumour microenvironment that promote therapeutic resistance. We highlight common mechanistic themes underpinning resistance to targeted therapies that are shared by NSCLC subtypes, including those with oncogenic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), ROS1 proto-oncogene receptor tyrosine kinase (ROS1), serine/threonine-protein kinase b-raf (BRAF) and other less established oncoproteins. Finally, we discuss how understanding these themes can inform therapeutic strategies, including combination therapy approaches, and overcome the challenge of tumour heterogeneity.
Audience	Academic
Author	Rotow, Julia Bivona, Trever G.
Author_xml	– sequence: 1 givenname: Julia surname: Rotow fullname: Rotow, Julia organization: Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco – sequence: 2 givenname: Trever G. surname: Bivona fullname: Bivona, Trever G. email: trever.bivona@ucsf.edu organization: Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, Cellular and Molecular Pharmacology, University of California San Francisco
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/29068003$$D View this record in MEDLINE/PubMed
BookMark	eNptkdtrFDEUxoNU7EWffJcBQQq6a5KZZBLfylIvsOiDFnwLZzMnuykzmTbJPPjfm2FbbcuSh5PL7_s4J98pOQpjQEJeM7pktFYfQ7RLTlm7VM0zcsKatlmwVqqjf3vx-5icpnRNKZOsZS_IMddUKkrrE_LpKnQYU4bQ-bCtSqkyxC3m-RQx-fnJYjWg3UHwaUiVD9X3n6v16iV57qBP-OqunpGrz5e_Vl8X6x9fvq0u1gvbCJ4XQtUaFHdOSeWw65gFsFx3deek4JZuNGXcSUcBawQt61bzhksQDUDNN5v6jJzvfW_ieDthymbwyWLfQ8BxSoZpIcpcstUFffsEvR6nGEp3e6qRUjf_qS30aHxwY45gZ1NzIRjjiotWFmp5gCqrw8HbEoHz5f6R4N0DwQ6hz7s09lP2Y0iPwTd3XU6bATtzE_0A8Y-5T6UAbA_YOKYU0RnrM8w-pQXfG0bNnLwpyZs5eaPmod4_0dzbHqY_7OlUqLDF-OCjDuB_AYPwuc0
CitedBy_id	crossref_primary_10_1158_2326_6066_CIR_18_0595 crossref_primary_10_3389_fonc_2021_658543 crossref_primary_10_3892_ol_2019_10372 crossref_primary_10_1089_ars_2017_7268 crossref_primary_10_1016_j_critrevonc_2021_103225 crossref_primary_10_1016_j_jtho_2019_11_018 crossref_primary_10_7554_eLife_50223 crossref_primary_10_1016_j_canlet_2022_215716 crossref_primary_10_1016_j_jare_2025_05_033 crossref_primary_10_1080_14686996_2022_2052181 crossref_primary_10_1007_s13402_025_01065_6 crossref_primary_10_1016_j_compbiomed_2022_105701 crossref_primary_10_1164_rccm_202410_1959PP crossref_primary_10_1016_j_lungcan_2023_107319 crossref_primary_10_7554_eLife_38579 crossref_primary_10_1038_s41598_023_38230_6 crossref_primary_10_1080_15384101_2021_1934625 crossref_primary_10_3892_or_2022_8467 crossref_primary_10_1016_j_biomaterials_2021_120946 crossref_primary_10_1016_j_cell_2020_05_043 crossref_primary_10_1016_j_jddst_2023_105128 crossref_primary_10_1016_j_bbrc_2021_11_099 crossref_primary_10_12677_WJCR_2022_122012 crossref_primary_10_3389_fphar_2022_829796 crossref_primary_10_1016_j_heliyon_2024_e32030 crossref_primary_10_1158_2159_8290_CD_18_1196 crossref_primary_10_1200_EDBK_432516 crossref_primary_10_1177_00368504211061971 crossref_primary_10_3390_ijms26072870 crossref_primary_10_1002_advs_202003263 crossref_primary_10_1002_onco_13590 crossref_primary_10_1016_j_critrevonc_2024_104284 crossref_primary_10_1016_j_immuni_2018_03_007 crossref_primary_10_1111_ijcp_14877 crossref_primary_10_1146_annurev_cancerbio_030419_033502 crossref_primary_10_3390_cancers14205144 crossref_primary_10_1186_s12957_021_02254_x crossref_primary_10_1007_s10735_025_10423_5 crossref_primary_10_1016_j_cancergen_2025_08_006 crossref_primary_10_1016_j_heliyon_2023_e16865 crossref_primary_10_1016_j_ejphar_2025_178096 crossref_primary_10_1016_j_jmoldx_2018_05_004 crossref_primary_10_1038_s41419_021_04369_1 crossref_primary_10_1016_j_jtho_2018_08_2025 crossref_primary_10_1016_j_phymed_2025_156604 crossref_primary_10_1007_s12094_022_02949_x crossref_primary_10_1186_s12885_022_10095_4 crossref_primary_10_3892_mco_2025_2857 crossref_primary_10_3389_fmed_2021_649177 crossref_primary_10_3390_cells11203200 crossref_primary_10_1007_s11523_020_00708_y crossref_primary_10_1186_s40425_019_0507_2 crossref_primary_10_3389_fonc_2024_1435537 crossref_primary_10_3892_ol_2019_10239 crossref_primary_10_1186_s12885_021_09044_4 crossref_primary_10_3390_cancers13194734 crossref_primary_10_1016_j_drup_2022_100852 crossref_primary_10_1038_s41420_025_02446_4 crossref_primary_10_1002_jcla_24714 crossref_primary_10_3389_fonc_2019_01503 crossref_primary_10_1159_000510103 crossref_primary_10_3390_cancers12061361 crossref_primary_10_1158_1078_0432_CCR_17_3492 crossref_primary_10_1186_s13046_021_02137_9 crossref_primary_10_1016_j_lfs_2018_03_005 crossref_primary_10_1155_2022_1475871 crossref_primary_10_1007_s12033_024_01127_4 crossref_primary_10_1002_ctm2_1024 crossref_primary_10_1016_j_ejphar_2020_173486 crossref_primary_10_1038_s41392_025_02243_6 crossref_primary_10_1097_COC_0000000000000985 crossref_primary_10_1016_j_ejphar_2019_172749 crossref_primary_10_1186_s13046_022_02505_z crossref_primary_10_1158_1541_7786_MCR_18_0731 crossref_primary_10_1007_s10585_025_10351_4 crossref_primary_10_1080_17476348_2020_1721285 crossref_primary_10_3390_cells11162618 crossref_primary_10_1007_s10637_019_00795_3 crossref_primary_10_1007_s10735_020_09943_z crossref_primary_10_1016_j_drup_2022_100863 crossref_primary_10_1038_s41416_021_01519_2 crossref_primary_10_1016_j_pharmthera_2019_107438 crossref_primary_10_1002_prp2_1047 crossref_primary_10_3389_fonc_2020_00729 crossref_primary_10_1186_s12935_022_02723_7 crossref_primary_10_3390_ph15111411 crossref_primary_10_3390_ijms26136226 crossref_primary_10_1016_j_csbj_2019_02_003 crossref_primary_10_1073_pnas_2313397121 crossref_primary_10_3389_fphar_2019_00260 crossref_primary_10_1016_j_ebiom_2019_01_053 crossref_primary_10_1016_j_omto_2020_05_012 crossref_primary_10_1158_0008_5472_CAN_20_3626 crossref_primary_10_1107_S2059798320014990 crossref_primary_10_1016_j_drup_2025_101245 crossref_primary_10_1371_journal_pone_0260720 crossref_primary_10_1016_j_phrs_2021_105701 crossref_primary_10_1186_s13000_021_01108_0 crossref_primary_10_1016_j_cll_2022_04_004 crossref_primary_10_1155_2022_4842454 crossref_primary_10_1186_s13045_018_0651_z crossref_primary_10_1038_s41420_022_01283_z crossref_primary_10_1146_annurev_pharmtox_033123_123610 crossref_primary_10_3389_fonc_2024_1447678 crossref_primary_10_1111_jcmm_14636 crossref_primary_10_1002_adma_202308977 crossref_primary_10_1016_j_pccm_2022_12_001 crossref_primary_10_1016_j_annonc_2025_05_538 crossref_primary_10_1111_his_13828 crossref_primary_10_1038_s41419_018_1162_0 crossref_primary_10_1080_07391102_2024_2448677 crossref_primary_10_1111_cas_14153 crossref_primary_10_3389_fgene_2022_949241 crossref_primary_10_1007_s00280_019_03902_6 crossref_primary_10_2147_OTT_S273794 crossref_primary_10_3389_fonc_2020_542277 crossref_primary_10_1002_1878_0261_12521 crossref_primary_10_1038_s41598_021_95985_6 crossref_primary_10_3389_fcell_2021_803198 crossref_primary_10_1038_s42003_021_02744_4 crossref_primary_10_1016_j_ccell_2021_07_006 crossref_primary_10_1038_s41598_025_85471_8 crossref_primary_10_1186_s10020_023_00602_z crossref_primary_10_3390_cancers12123729 crossref_primary_10_3390_jpm12101544 crossref_primary_10_1016_j_drup_2021_100770 crossref_primary_10_3892_ol_2021_12924 crossref_primary_10_1002_mc_22901 crossref_primary_10_1007_s00210_025_04576_z crossref_primary_10_1097_CAD_0000000000001537 crossref_primary_10_1016_j_canlet_2021_07_031 crossref_primary_10_1016_j_celrep_2025_116323 crossref_primary_10_3389_fphar_2022_900825 crossref_primary_10_3892_or_2025_8944 crossref_primary_10_1016_j_ejmech_2020_112755 crossref_primary_10_1016_j_tox_2022_153141 crossref_primary_10_1038_s41388_022_02241_w crossref_primary_10_1016_j_jtho_2019_03_003 crossref_primary_10_2147_OTT_S261799 crossref_primary_10_3390_jpm11111102 crossref_primary_10_3390_biomedicines11092555 crossref_primary_10_1016_j_jtho_2022_10_015 crossref_primary_10_3389_fimmu_2024_1369118 crossref_primary_10_1186_s12964_019_0347_1 crossref_primary_10_3390_ijms24054827 crossref_primary_10_1080_13543784_2024_2305134 crossref_primary_10_1016_j_cbi_2021_109652 crossref_primary_10_3390_cancers16040710 crossref_primary_10_1177_1758835920947976 crossref_primary_10_1080_2162402X_2021_1951019 crossref_primary_10_3390_cancers14102478 crossref_primary_10_1016_j_cels_2019_10_002 crossref_primary_10_1016_S1875_5364_21_60027_4 crossref_primary_10_1016_j_cell_2020_03_022 crossref_primary_10_1038_s41388_024_03244_5 crossref_primary_10_1371_journal_pone_0281558 crossref_primary_10_1016_j_omto_2023_02_007 crossref_primary_10_1016_j_canlet_2024_216762 crossref_primary_10_1016_j_cllc_2022_12_003 crossref_primary_10_3390_ijms25094844 crossref_primary_10_1158_0008_5472_CAN_18_1492 crossref_primary_10_1007_s11010_023_04704_4 crossref_primary_10_1038_s41388_023_02810_7 crossref_primary_10_3389_fphar_2021_680589 crossref_primary_10_3390_cancers13020272 crossref_primary_10_1002_jcb_29714 crossref_primary_10_3389_fphar_2021_625289 crossref_primary_10_26508_lsa_202302060 crossref_primary_10_1111_1759_7714_14229 crossref_primary_10_1016_j_canlet_2019_09_005 crossref_primary_10_3390_ijms241512222 crossref_primary_10_3390_biomedicines9020123 crossref_primary_10_1039_D1BM00634G crossref_primary_10_1080_14756366_2023_2227779 crossref_primary_10_1016_j_jtho_2021_06_013 crossref_primary_10_1016_j_annonc_2020_01_013 crossref_primary_10_1158_1078_0432_CCR_20_3854 crossref_primary_10_1016_j_critrevonc_2020_103119 crossref_primary_10_1158_1078_0432_CCR_19_2777 crossref_primary_10_3389_fgene_2020_602035 crossref_primary_10_3390_ijms252212402 crossref_primary_10_1016_j_bcp_2024_116251 crossref_primary_10_3390_cancers13071613 crossref_primary_10_1111_jcmm_15887 crossref_primary_10_2147_OTT_S244339 crossref_primary_10_1186_s12967_021_03056_1 crossref_primary_10_3892_ol_2021_12954 crossref_primary_10_3389_fmicb_2022_968053 crossref_primary_10_1172_JCI124049 crossref_primary_10_1021_acsptsci_5c00235 crossref_primary_10_1186_s12931_024_02844_9 crossref_primary_10_1186_s12957_024_03435_0 crossref_primary_10_1016_j_gene_2024_148566 crossref_primary_10_2147_OTT_S305388 crossref_primary_10_1186_s13046_020_01555_5 crossref_primary_10_1080_17512433_2019_1649136 crossref_primary_10_1016_j_toxlet_2018_04_024 crossref_primary_10_1186_s13046_018_0735_1 crossref_primary_10_3390_biom13040689 crossref_primary_10_1186_s12957_022_02566_6 crossref_primary_10_1016_j_canlet_2020_01_004 crossref_primary_10_1177_08853282241228667 crossref_primary_10_3892_ol_2022_13301 crossref_primary_10_1016_j_lungcan_2018_12_010 crossref_primary_10_1016_j_repbio_2022_100680 crossref_primary_10_1038_s41591_021_01450_2 crossref_primary_10_3389_fonc_2021_664290 crossref_primary_10_1016_j_jbc_2023_104814 crossref_primary_10_3390_cancers13225639 crossref_primary_10_1007_s12032_023_02184_6 crossref_primary_10_1089_gtmb_2022_0004 crossref_primary_10_1016_j_heliyon_2024_e29383 crossref_primary_10_3390_cancers17152424 crossref_primary_10_1016_j_ejmech_2025_117903 crossref_primary_10_1371_journal_pone_0220567 crossref_primary_10_1007_s00270_020_02550_1 crossref_primary_10_1016_j_ijbiomac_2021_10_113 crossref_primary_10_3390_ijms22189712 crossref_primary_10_1002_tox_22582 crossref_primary_10_1177_1078155218781944 crossref_primary_10_1038_s41401_020_0442_2 crossref_primary_10_1038_s41420_025_02310_5 crossref_primary_10_1007_s11845_019_02137_x crossref_primary_10_1080_03639045_2022_2098316 crossref_primary_10_1186_s12935_019_0939_2 crossref_primary_10_3389_fonc_2021_602900 crossref_primary_10_1016_j_cbi_2023_110516 crossref_primary_10_1038_s41594_019_0358_z crossref_primary_10_1158_1078_0432_CCR_19_3608 crossref_primary_10_3389_fonc_2022_861271 crossref_primary_10_3390_ijms24055046 crossref_primary_10_3389_fonc_2024_1430350 crossref_primary_10_3390_ph13110413 crossref_primary_10_1136_jitc_2024_010926 crossref_primary_10_12998_wjcc_v10_i33_12164 crossref_primary_10_3390_biomedicines9030243 crossref_primary_10_3390_ijms232315056 crossref_primary_10_3892_ol_2022_13528 crossref_primary_10_1016_j_drup_2023_100958 crossref_primary_10_1007_s11864_022_01022_7 crossref_primary_10_3390_ijms23073631 crossref_primary_10_1016_j_jbc_2022_101563 crossref_primary_10_1038_s41571_020_0341_y crossref_primary_10_1007_s40265_021_01477_2 crossref_primary_10_3390_ijms26072957 crossref_primary_10_1016_j_bmc_2024_117967 crossref_primary_10_1042_BSR20201541 crossref_primary_10_1002_cam4_2115 crossref_primary_10_1111_cas_14786 crossref_primary_10_1016_j_intimp_2024_112157 crossref_primary_10_3390_cancers13235974 crossref_primary_10_1093_oncolo_oyaf029 crossref_primary_10_1002_jcb_29402 crossref_primary_10_1371_journal_pcbi_1009348 crossref_primary_10_1177_2050313X19832160 crossref_primary_10_1016_j_lungcan_2022_04_001 crossref_primary_10_1016_j_lungcan_2022_04_002 crossref_primary_10_1038_s41573_022_00615_z crossref_primary_10_1016_j_prp_2023_154848 crossref_primary_10_1177_1758835918797589 crossref_primary_10_3390_cancers12010040 crossref_primary_10_1007_s13402_024_00999_7 crossref_primary_10_3389_fphar_2021_671328 crossref_primary_10_1155_2023_1367938 crossref_primary_10_1016_j_molstruc_2021_131066 crossref_primary_10_1016_j_lungcan_2018_07_030 crossref_primary_10_1016_j_celrep_2023_113417 crossref_primary_10_1038_s41401_020_00513_3 crossref_primary_10_1007_s00292_020_00793_w crossref_primary_10_1080_14756366_2022_2046567 crossref_primary_10_1186_s43556_022_00107_x crossref_primary_10_1002_cam4_2244 crossref_primary_10_1016_j_molstruc_2022_134619 crossref_primary_10_1016_j_bbamcr_2021_119144 crossref_primary_10_3390_cancers13050941 crossref_primary_10_1371_journal_pone_0258951 crossref_primary_10_1007_s00280_019_03863_w crossref_primary_10_3390_vaccines8020166 crossref_primary_10_3389_fonc_2022_1024818 crossref_primary_10_1186_s40425_019_0660_7 crossref_primary_10_1016_j_ebiom_2020_103067 crossref_primary_10_1016_j_intimp_2021_107594 crossref_primary_10_1002_jso_25937 crossref_primary_10_3390_cancers15235500 crossref_primary_10_3892_ol_2019_10791 crossref_primary_10_1080_14737140_2018_1432356 crossref_primary_10_1038_s41420_022_00966_x crossref_primary_10_3389_fonc_2022_911303 crossref_primary_10_1080_17476348_2019_1656068 crossref_primary_10_1002_cam4_4676 crossref_primary_10_1016_j_critrevonc_2025_104870 crossref_primary_10_1002_cbin_11494 crossref_primary_10_3390_cancers12061609 crossref_primary_10_1016_j_ccell_2018_11_007 crossref_primary_10_3389_fphar_2022_997842 crossref_primary_10_1038_s41568_018_0070_z crossref_primary_10_1172_JCI96148 crossref_primary_10_1097_CAD_0000000000000831 crossref_primary_10_1016_j_lfs_2018_07_023 crossref_primary_10_1016_j_cell_2021_03_031 crossref_primary_10_1038_s41698_025_00893_x crossref_primary_10_1111_1759_7714_15165 crossref_primary_10_1016_j_phrs_2021_105583 crossref_primary_10_1038_s41467_021_24841_y crossref_primary_10_3389_fcell_2021_663147 crossref_primary_10_1038_s41571_023_00736_3 crossref_primary_10_1002_asia_202401842 crossref_primary_10_1016_j_canlet_2023_216400 crossref_primary_10_1136_bmjopen_2022_060782 crossref_primary_10_1158_1078_0432_CCR_19_1176 crossref_primary_10_1038_s41467_021_21884_z crossref_primary_10_1038_s41698_025_00991_w crossref_primary_10_1016_j_addr_2024_115476 crossref_primary_10_1111_imr_13274 crossref_primary_10_1007_s00432_022_03975_6 crossref_primary_10_1016_j_semcancer_2019_10_019 crossref_primary_10_1038_s12276_025_01493_2 crossref_primary_10_1002_jcp_28977 crossref_primary_10_2147_PGPM_S418320 crossref_primary_10_3390_biomedicines9040359 crossref_primary_10_1007_s13258_021_01179_9 crossref_primary_10_1016_j_celrep_2024_114613 crossref_primary_10_1016_j_bioorg_2025_108660 crossref_primary_10_4103_jcrt_jcrt_1286_22 crossref_primary_10_1016_j_ejca_2022_06_008 crossref_primary_10_1038_s41598_024_55717_y crossref_primary_10_1038_s41598_019_55060_7 crossref_primary_10_1038_s41598_023_28821_8 crossref_primary_10_2217_fon_2020_0583 crossref_primary_10_1016_j_cancergen_2023_08_003 crossref_primary_10_1002_ptr_7682 crossref_primary_10_1186_s12943_025_02259_0 crossref_primary_10_2147_DDDT_S416091 crossref_primary_10_3390_jfb14090466 crossref_primary_10_1186_s12935_023_03055_w crossref_primary_10_3389_fcell_2024_1511190 crossref_primary_10_1016_j_lungcan_2019_03_018 crossref_primary_10_1016_S0140_6736_21_00312_3 crossref_primary_10_3390_life11070682 crossref_primary_10_1016_j_canlet_2022_216025 crossref_primary_10_3390_cancers13050987 crossref_primary_10_7759_cureus_92202 crossref_primary_10_1016_j_freeradbiomed_2018_09_016 crossref_primary_10_5937_afmnai41_49136 crossref_primary_10_1186_s12951_023_02078_9 crossref_primary_10_1017_erm_2022_9 crossref_primary_10_1371_journal_pcbi_1007278 crossref_primary_10_1016_j_apsb_2019_10_011 crossref_primary_10_1039_D0SC01676D crossref_primary_10_1002_smll_201802372 crossref_primary_10_1159_000507850 crossref_primary_10_2147_CMAR_S261131 crossref_primary_10_3390_cancers16244225 crossref_primary_10_1016_j_seppur_2020_117343 crossref_primary_10_1002_advs_201903700 crossref_primary_10_1038_s41420_023_01701_w crossref_primary_10_1158_1078_0432_CCR_19_3321 crossref_primary_10_1126_scitranslmed_abg6428 crossref_primary_10_1016_j_intimp_2024_113264 crossref_primary_10_3892_ijo_2024_5665 crossref_primary_10_1016_j_canlet_2019_114428 crossref_primary_10_1038_s41467_021_27276_7 crossref_primary_10_1155_2020_9601876 crossref_primary_10_1016_j_omtn_2020_09_024 crossref_primary_10_3390_ph14020130 crossref_primary_10_1016_j_taap_2024_116807 crossref_primary_10_1016_j_fct_2019_110654 crossref_primary_10_1016_j_cllc_2023_03_008 crossref_primary_10_1002_prp2_528 crossref_primary_10_1016_j_taap_2025_117280 crossref_primary_10_15252_emmm_201809960 crossref_primary_10_3389_fphar_2020_01094 crossref_primary_10_1016_j_ejps_2023_106516 crossref_primary_10_1016_j_heliyon_2020_e05639 crossref_primary_10_1097_MD_0000000000037229 crossref_primary_10_1093_oncolo_oyae344 crossref_primary_10_1186_s12896_024_00854_5 crossref_primary_10_1002_1878_0261_13290 crossref_primary_10_3390_cancers14143452 crossref_primary_10_3390_cells10102620 crossref_primary_10_1002_jcb_28148 crossref_primary_10_3389_fonc_2021_760715 crossref_primary_10_1155_2022_2262014 crossref_primary_10_1002_mds3_10067 crossref_primary_10_1016_j_cell_2020_07_017 crossref_primary_10_1016_S0007_4551_25_00153_5 crossref_primary_10_3892_ijo_2024_5714 crossref_primary_10_1016_j_semcancer_2021_06_011 crossref_primary_10_1007_s00204_024_03693_7 crossref_primary_10_1016_j_aca_2023_342158 crossref_primary_10_1038_s41392_020_0116_z crossref_primary_10_3390_cells13211752 crossref_primary_10_2147_OTT_S254464 crossref_primary_10_1016_j_canlet_2022_215583 crossref_primary_10_1016_j_lungcan_2021_09_001 crossref_primary_10_3892_ol_2023_13909 crossref_primary_10_1186_s12935_024_03510_2 crossref_primary_10_1097_JCMA_0000000000000438 crossref_primary_10_1002_mc_23306 crossref_primary_10_1186_s12957_023_03203_6 crossref_primary_10_1016_j_ctrv_2022_102430 crossref_primary_10_1016_j_ejmech_2021_113335 crossref_primary_10_1016_j_jbc_2025_110656 crossref_primary_10_1080_01635581_2024_2383336 crossref_primary_10_1080_13880209_2021_1972122 crossref_primary_10_1158_1078_0432_CCR_22_1912 crossref_primary_10_1016_j_bbrc_2018_06_087 crossref_primary_10_1158_2159_8290_CD_19_1446 crossref_primary_10_1111_jcmm_17799 crossref_primary_10_1158_2159_8290_CD_19_0597 crossref_primary_10_1007_s12539_025_00699_2 crossref_primary_10_1007_s00335_021_09919_8 crossref_primary_10_2147_IJN_S359300 crossref_primary_10_7554_eLife_66788 crossref_primary_10_1111_imcb_12404 crossref_primary_10_1111_jcmm_16340 crossref_primary_10_3390_cryst14020106 crossref_primary_10_1038_s41598_018_38068_3 crossref_primary_10_3389_fonc_2022_993781 crossref_primary_10_1016_j_bioorg_2023_106936 crossref_primary_10_1093_nar_gkx1218 crossref_primary_10_12688_f1000research_19592_1 crossref_primary_10_1016_j_biopha_2022_112909 crossref_primary_10_1111_1759_7714_14141 crossref_primary_10_1016_j_tranon_2022_101367 crossref_primary_10_3389_fonc_2022_740051 crossref_primary_10_1002_ijc_34127 crossref_primary_10_1002_wnan_1654 crossref_primary_10_1073_pnas_2313137120 crossref_primary_10_1080_14737140_2021_1923485 crossref_primary_10_3389_fgene_2022_881875 crossref_primary_10_3389_fimmu_2023_1235575 crossref_primary_10_1007_s13402_020_00515_7 crossref_primary_10_1016_j_jconrel_2024_08_035 crossref_primary_10_1016_j_gpb_2022_10_006 crossref_primary_10_1016_j_jtho_2020_11_014 crossref_primary_10_1158_1078_0432_CCR_18_0040 crossref_primary_10_1007_s00432_021_03828_8 crossref_primary_10_3390_pharmaceutics13050747 crossref_primary_10_1016_j_pccm_2023_08_006 crossref_primary_10_1016_j_bbcan_2020_188363 crossref_primary_10_1186_s12943_020_01202_9 crossref_primary_10_1155_2023_4025734 crossref_primary_10_1007_s10565_019_09503_6 crossref_primary_10_1172_JCI160152 crossref_primary_10_1177_03008916211005546 crossref_primary_10_1515_hsz_2020_0144 crossref_primary_10_1016_j_phymed_2024_155657 crossref_primary_10_3389_fonc_2021_708294 crossref_primary_10_1016_j_porgcoat_2020_106098 crossref_primary_10_1016_j_cancergen_2021_03_006 crossref_primary_10_1038_s41598_023_30565_4 crossref_primary_10_1158_0008_5472_CAN_22_1549 crossref_primary_10_1016_j_bcp_2022_115294 crossref_primary_10_3892_ijo_2019_4805 crossref_primary_10_1016_j_currproblcancer_2024_101106 crossref_primary_10_3892_ijmm_2019_4386 crossref_primary_10_1186_s12890_020_01276_7 crossref_primary_10_1080_17435889_2024_2370225 crossref_primary_10_1002_2211_5463_70125 crossref_primary_10_3390_ijms242115906 crossref_primary_10_1002_bmc_70003 crossref_primary_10_3390_ijms242115801 crossref_primary_10_1016_j_tips_2020_02_001 crossref_primary_10_1039_D5MD00141B crossref_primary_10_1016_j_jddst_2025_107250 crossref_primary_10_1016_j_jtho_2025_06_011 crossref_primary_10_3389_fphar_2018_00082 crossref_primary_10_1016_j_molmed_2018_12_009 crossref_primary_10_1080_17435889_2024_2348438 crossref_primary_10_1155_2022_1930604 crossref_primary_10_1186_s12935_024_03282_9 crossref_primary_10_1021_acsami_5c04021 crossref_primary_10_1016_j_bioorg_2025_108820 crossref_primary_10_1016_j_phrs_2020_105110 crossref_primary_10_3390_ijms25095033 crossref_primary_10_1038_s41698_021_00203_1 crossref_primary_10_1158_2159_8290_CD_21_0910 crossref_primary_10_1186_s12935_025_03657_6 crossref_primary_10_1016_j_omtn_2023_102030 crossref_primary_10_1172_JCI164413 crossref_primary_10_3390_pharmaceutics17070945 crossref_primary_10_1016_j_critrevonc_2023_103966 crossref_primary_10_1172_JCI122779 crossref_primary_10_1186_s11671_021_03580_5 crossref_primary_10_1186_s12964_025_02104_3 crossref_primary_10_3390_cells9092083 crossref_primary_10_1038_s41392_025_02358_w crossref_primary_10_1038_s41419_021_03439_8 crossref_primary_10_1016_j_bulcan_2020_05_008 crossref_primary_10_1007_s11684_022_0976_4 crossref_primary_10_1016_j_cllc_2020_07_007 crossref_primary_10_3389_fgene_2022_1008416 crossref_primary_10_1038_s41556_018_0264_3 crossref_primary_10_1007_s40265_019_01164_3 crossref_primary_10_1016_j_lungcan_2024_107533 crossref_primary_10_1097_CAD_0000000000001575 crossref_primary_10_3390_molecules27072259 crossref_primary_10_1016_j_pharmthera_2021_107827 crossref_primary_10_3390_cancers15030722 crossref_primary_10_1016_j_actbio_2024_07_020 crossref_primary_10_1016_j_jtcvs_2017_12_111 crossref_primary_10_1016_j_ejps_2021_106004 crossref_primary_10_1158_0008_5472_CAN_18_0757 crossref_primary_10_1177_09731296251355018 crossref_primary_10_1080_14737140_2022_2116004 crossref_primary_10_1177_17588359251338046 crossref_primary_10_1007_s00018_020_03691_9 crossref_primary_10_1016_j_semcancer_2019_03_006 crossref_primary_10_1016_j_lfs_2024_122614 crossref_primary_10_2147_OTT_S295102 crossref_primary_10_1016_j_cbpa_2020_11_007 crossref_primary_10_1080_14789450_2018_1429924 crossref_primary_10_34172_aim_2022_72 crossref_primary_10_3390_ijms22126587 crossref_primary_10_1038_s41417_020_00214_3 crossref_primary_10_1088_1755_1315_276_1_012003 crossref_primary_10_2147_CMAR_S313744 crossref_primary_10_3390_biomedicines13071653 crossref_primary_10_3389_fimmu_2024_1320244 crossref_primary_10_1186_s11658_019_0193_6 crossref_primary_10_3389_fonc_2023_1137966 crossref_primary_10_1016_j_cllc_2018_11_014 crossref_primary_10_1186_s13046_018_0894_0 crossref_primary_10_3389_fmed_2023_1203461 crossref_primary_10_1016_j_ejmech_2023_115935 crossref_primary_10_7717_peerj_15678 crossref_primary_10_1002_jor_24771 crossref_primary_10_1016_j_bbcan_2018_10_001 crossref_primary_10_1158_1541_7786_MCR_20_0818 crossref_primary_10_2147_LCTT_S293902 crossref_primary_10_1016_j_ebiom_2019_07_071 crossref_primary_10_1097_MD_0000000000029682 crossref_primary_10_3389_fonc_2022_1031802 crossref_primary_10_1002_ardp_202400992 crossref_primary_10_1016_j_yexcr_2021_112868 crossref_primary_10_1136_jitc_2024_009092 crossref_primary_10_3390_cancers14133243 crossref_primary_10_1038_s41401_024_01451_0 crossref_primary_10_1038_s41422_020_00409_1 crossref_primary_10_3390_ijms19113448 crossref_primary_10_1002_1878_0261_13446 crossref_primary_10_1016_j_jtho_2025_07_009 crossref_primary_10_1007_s11051_024_06023_1 crossref_primary_10_1186_s12935_021_02427_4 crossref_primary_10_1016_j_lungcan_2019_05_032 crossref_primary_10_1016_j_lungcan_2020_04_002 crossref_primary_10_1016_j_tiv_2024_105801 crossref_primary_10_1158_1078_0432_CCR_18_1635 crossref_primary_10_1038_d41586_019_01934_9 crossref_primary_10_1186_s13045_018_0594_4 crossref_primary_10_3389_fonc_2021_763035 crossref_primary_10_1038_s41598_023_32238_8 crossref_primary_10_1188_18_CJON_113_115 crossref_primary_10_3389_fimmu_2019_03135 crossref_primary_10_1016_j_jtocrr_2022_100436 crossref_primary_10_3390_genes15070906 crossref_primary_10_1016_j_bbrc_2022_10_026 crossref_primary_10_1038_s41420_024_02220_y crossref_primary_10_61882_jcbior_6_2_299 crossref_primary_10_1038_s41598_025_15624_2 crossref_primary_10_1016_j_canlet_2020_07_043 crossref_primary_10_1038_s42003_018_0050_6 crossref_primary_10_1186_s13045_022_01224_4 crossref_primary_10_1080_01635581_2019_1610183 crossref_primary_10_1177_03008916241261484 crossref_primary_10_1016_j_ejca_2022_06_037 crossref_primary_10_1038_s41598_019_40571_0 crossref_primary_10_1080_21655979_2021_1943109 crossref_primary_10_1016_j_lungcan_2020_12_037 crossref_primary_10_1016_j_bcp_2018_12_010 crossref_primary_10_1111_bjh_18953 crossref_primary_10_1186_s13046_023_02606_3 crossref_primary_10_3390_cancers12102783 crossref_primary_10_3892_ol_2023_14126 crossref_primary_10_1016_j_biocel_2018_06_006 crossref_primary_10_1007_s40291_021_00515_9 crossref_primary_10_3389_fimmu_2022_811007 crossref_primary_10_1002_iub_2914 crossref_primary_10_1038_s41419_023_06069_4 crossref_primary_10_1155_2020_8837254 crossref_primary_10_1016_j_lungcan_2023_107253 crossref_primary_10_1038_s41598_025_15056_y crossref_primary_10_3390_molecules28124672 crossref_primary_10_1016_j_jprot_2021_104122 crossref_primary_10_1097_CCO_0000000000000598 crossref_primary_10_1111_bph_14793 crossref_primary_10_1038_s41598_023_37006_2 crossref_primary_10_1002_1878_0261_13429 crossref_primary_10_1016_j_cellsig_2023_110851 crossref_primary_10_2217_pgs_2020_0021 crossref_primary_10_1002_adma_202201516 crossref_primary_10_1038_s41467_020_15615_z crossref_primary_10_1097_MD_0000000000027038 crossref_primary_10_1002_1878_0261_13564 crossref_primary_10_1007_s13691_025_00745_2 crossref_primary_10_1016_j_pharmthera_2019_02_010 crossref_primary_10_1038_s41388_025_03502_0 crossref_primary_10_1093_bib_bbab187 crossref_primary_10_1177_17588359231225046 crossref_primary_10_1007_s00761_020_00748_z crossref_primary_10_3390_cancers15020504 crossref_primary_10_1053_j_seminoncol_2018_05_002 crossref_primary_10_1371_journal_pone_0264717 crossref_primary_10_3389_fimmu_2025_1572802 crossref_primary_10_1038_s12276_022_00835_8 crossref_primary_10_1038_s41388_024_03130_0 crossref_primary_10_1016_j_bbcan_2023_188987 crossref_primary_10_1016_j_cllc_2025_08_009 crossref_primary_10_1186_s13287_022_02859_3 crossref_primary_10_1016_j_neo_2021_08_003 crossref_primary_10_1016_j_mito_2024_101919 crossref_primary_10_1007_s10555_025_10272_4
Cites_doi	10.1038/nm.3352 10.1158/2159-8290.CD-15-0063 10.1126/science.1141478 10.1073/pnas.74.7.2790 10.1016/j.jtho.2016.09.131 10.1200/JCO.2011.35.6345 10.1016/j.ccell.2015.02.005 10.1158/1078-0432.CCR-16-0399 10.1038/nature09870 10.1158/1078-0432.CCR-09-1001 10.1016/S1470-2045(11)70184-X 10.1056/NEJMoa1406766 10.3892/ol.2015.3945 10.1158/1078-0432.CCR-16-2271 10.1158/1078-0432.CCR-13-2613 10.1073/pnas.81.1.71 10.1093/annonc/mdv573 10.1186/2162-3619-3-26 10.1002/2211-5463.12162 10.1038/nature22364 10.1016/S1470-2045(16)30561-7 10.1038/nature12796 10.1073/pnas.1203530109 10.1038/nrm3012 10.1158/2159-8290.CD-16-1123 10.1158/0008-5472.CAN-16-3404 10.1056/NEJMoa1508887 10.1200/JCO.2009.26.7609 10.1016/j.jtho.2016.11.274 10.1158/0008-5472.CAN-15-0717 10.1016/S1556-0864(16)30324-0 10.18632/oncotarget.2397 10.1002/ijc.27403 10.1016/j.lungcan.2016.10.015 10.1097/JTO.0000000000000688 10.1056/NEJMoa1616288 10.1126/scitranslmed.3003316 10.1111/j.1349-7006.2010.01511.x 10.1016/j.jocn.2015.05.068 10.1038/nm.3667 10.1038/ncomms12231 10.1371/journal.pone.0082236 10.1158/0008-5472.CAN-16-2432 10.1200/JCO.2016.70.9352 10.1158/1535-7163.MCT-16-0258 10.1016/j.jtcvs.2010.11.056 10.1097/JTO.0b013e3181ec1531 10.1200/JCO.2012.47.4189 10.1038/nrc3876 10.1158/0008-5472.CAN-05-1988 10.1158/1078-0432.CCR-15-2377 10.1158/1078-0432.CCR-12-0912 10.1586/era.12.17 10.1158/2159-8290.CD-15-0940 10.1200/jco.2014.32.15_suppl.8001 10.1038/srep44206 10.1158/1078-0432.CCR-15-0589 10.1016/j.jtho.2016.06.013 10.1016/j.molonc.2013.08.001 10.1093/annonc/mdt573 10.1073/pnas.1610456113 10.1097/JTO.0000000000000344 10.1200/JCO.2010.34.1313 10.1016/j.ccell.2015.08.001 10.1038/nm.3930 10.1016/j.neo.2016.02.001 10.1111/j.1349-7006.2009.01368.x 10.1038/ncb1993 10.1016/S1097-2765(01)00378-1 10.1016/j.jtho.2016.09.119 10.1038/clpt.2012.73 10.1158/1078-0432.CCR-15-0016 10.1158/1078-0432.CCR-11-2906 10.1016/j.canlet.2016.06.002 10.1158/1078-0432.CCR-15-2013 10.1158/1078-0432.CCR-12-1558 10.1158/2159-8290.CD-13-0846 10.1200/JCO.2016.34.15_suppl.9065 10.1016/j.jmoldx.2013.11.007 10.1158/1078-0432.CCR-16-3273 10.1200/JCO.2009.25.4029 10.1016/S1470-2045(16)30392-8 10.1186/s12885-015-1967-5 10.1016/j.lungcan.2017.04.003 10.1200/jco.2014.32.15_suppl.8045 10.1158/2159-8290.CD-13-0310 10.1021/jm401427c 10.1158/2159-8290.CD-13-0741 10.1200/JCO.2012.44.2806 10.1001/jamaoncol.2016.0405 10.1111/cas.13111 10.1126/science.8122112 10.1097/JTO.0000000000000113 10.1158/1535-7163.MCT-15-0084 10.1158/1535-7163.MCT-12-0311 10.1016/j.biopha.2015.10.018 10.1093/annonc/mdh031 10.1073/pnas.1009472107 10.1038/nm.2673 10.1158/2159-8290.CD-13-0314 10.1056/NEJMoa1502309 10.1200/JCO.2008.19.1635 10.1056/NEJMoa1215530 10.1056/NEJMoa1704795 10.1038/ng.3218 10.1016/j.cllc.2012.06.004 10.1158/1078-0432.CCR-12-2246 10.1158/1078-0432.CCR-16-0917 10.1097/JTO.0b013e3182721ed1 10.1038/nm.4091 10.1158/0008-5472.CAN-06-1684 10.1016/j.jtho.2015.12.097 10.2147/HP.S93413 10.1007/s00280-014-2664-9 10.1038/nature14982 10.1007/s00280-017-3283-z 10.1016/j.celrep.2015.01.040 10.1056/NEJMoa040938 10.1200/JCO.2016.34.15_suppl.9059 10.1001/jamaoncol.2015.1066 10.1016/j.cellsig.2007.06.023 10.1200/JCO.2011.35.9638 10.1038/nature17960 10.1021/jm500261q 10.1056/NEJMoa1007478 10.3816/CLC.2004.n.004 10.1158/0008-5472.CAN-14-3167 10.1038/nm.4040 10.1016/j.ccr.2014.02.025 10.1016/j.bbrc.2016.04.089 10.1016/j.jtho.2016.11.1496 10.1126/scitranslmed.3007205 10.1158/1078-0432.CCR-14-1511 10.1158/1078-0432.CCR-15-1031 10.1200/jco.2014.32.15_suppl.8026 10.1186/s12885-017-3263-z 10.3349/ymj.2017.58.1.9 10.1158/2159-8290.CD-16-0686 10.1371/journal.pmed.0020073 10.1038/nature05945 10.1016/S1470-2045(16)30532-0 10.1016/j.jtho.2016.01.022 10.1097/JTO.0b013e3182629903 10.1073/pnas.1320956111 10.1016/j.lungcan.2014.02.011 10.1097/JTO.0b013e3182745948 10.1038/nm.2713 10.1016/S1470-2045(16)00077-2 10.1158/0008-5472.CAN-08-4055 10.1016/j.celrep.2015.03.012 10.1200/JCO.2016.34.15_suppl.9072 10.18632/oncotarget.3311 10.3892/ijo.2014.2574 10.1158/2159-8290.CD-14-0337 10.1016/j.jtho.2016.11.398 10.1073/pnas.0709662105 10.1097/JTO.0000000000000380 10.1038/srep17499 10.1002/cncr.30677 10.1016/j.cell.2010.02.027 10.1038/ncomms14768 10.2147/OTT.S89659 10.1158/1535-7163.MCT-14-0274 10.1073/pnas.1220843110 10.1097/CAD.0000000000000489 10.1111/cas.12996 10.1056/NEJMoa0904554 10.1158/1078-0432.CCR-14-1901 10.1158/1535-7163.MCT-10-0502 10.1016/S0960-9822(99)80265-6 10.1158/1078-0432.CCR-13-2233 10.1097/01.JTO.0000473485.38553.f0 10.1038/431525b 10.1073/pnas.1522052113 10.1158/1078-0432.CCR-15-3101 10.1158/1078-0432.CCR-11-1648 10.1126/scisignal.aac8460 10.1158/1078-0432.CCR-08-0151 10.1038/ng.2330 10.1016/j.jtho.2016.11.270 10.1158/2159-8290.CD-12-0103 10.1158/0008-5472.CAN-17-0109 10.1056/NEJMoa1612674 10.1038/nm.2658 10.1158/0008-5472.CAN-12-4502 10.1016/0006-2952(94)90042-6 10.3816/CLC.2010.n.046 10.1016/j.jtho.2016.08.126 10.1016/j.cell.2012.08.029 10.1101/gr.133645.111 10.1093/jnci/dji055 10.1038/ncomms7377 10.1097/JTO.0b013e318293d96f 10.1634/theoncologist.2014-0228 10.1084/jem.20131195 10.1200/jco.2014.32.15_suppl.8017 10.1158/1535-7163.MCT-17-0008 10.1158/2159-8290.CD-13-0035 10.1016/j.cell.2007.11.025 10.1126/science.aad6204 10.1158/1541-7786.MCR-09-0460 10.1200/JCO.2004.04.105 10.1158/1078-0432.CCR-06-2854 10.1158/1078-0432.CCR-06-0714 10.1158/0008-5472.CAN-10-4433 10.1097/JTO.0b013e3181913e0e 10.1016/j.jtho.2016.04.001 10.1016/j.ccr.2014.05.019 10.1038/nm.3854 10.1158/1535-7163.MCT-05-0149 10.1073/pnas.1404639111 10.1158/0008-5472.CAN-07-6186 10.1158/0008-5472.CAN-10-2956 10.1126/science.1254721 10.1056/NEJMoa044238 10.1038/ncomms10690 10.1371/journal.pmed.0040294 10.1038/nm.1890 10.1200/JCO.2014.58.1736 10.1634/theoncologist.2009-0009 10.1111/j.1349-7006.2012.02408.x 10.1016/j.lungcan.2015.11.016 10.1172/JCI28656 10.1093/annonc/mdv186 10.1016/j.phrs.2012.11.007 10.1158/1078-0432.CCR-11-2972 10.1158/2159-8290.CD-12-0108 10.1158/1078-0432.CCR-12-0392 10.1038/ncomms5846 10.1016/j.lungcan.2013.09.019 10.1007/s00280-012-1929-4 10.1056/NEJMoa1408440 10.1158/1078-0432.CCR-08-1757 10.1186/s13045-016-0296-8 10.1158/1078-0432.CCR-14-0846 10.1371/journal.pone.0086459 10.1016/j.jtho.2016.11.2231 10.1016/j.jtho.2016.08.140 10.1371/journal.pone.0041017 10.1200/jco.2014.32.15_suppl.10018 10.1097/JTO.0000000000000048 10.1016/j.lungcan.2012.01.008 10.1038/srep32258 10.1001/jama.2014.3741 10.1200/JCO.2016.34.15_suppl.108 10.1158/1078-0432.CCR-15-1458 10.1038/nature18600 10.1097/JTO.0000000000000088 10.1016/S1470-2045(16)30146-2 10.1016/S2213-2600(17)30129-7 10.1200/JCO.2010.34.0570 10.1016/j.celrep.2014.05.039 10.1002/cncr.28964 10.1200/jco.2015.33.15_suppl.8064 10.1158/2159-8290.CD-14-1467 10.1016/j.jtho.2016.10.014 10.1007/s00280-014-2578-6 10.1158/1078-0432.CCR-13-2482 10.1038/35052073 10.1158/1078-0432.CCR-14-1350 10.1158/1078-0432.CCR-16-0569 10.1056/NEJMc060020 10.1371/journal.pone.0171280 10.1158/2159-8290.CD-15-0285 10.1158/0008-5472.CAN-04-2650 10.1371/journal.pone.0147344 10.1200/JCO.2010.33.1280 10.1200/jco.2015.33.15_suppl.2509 10.1158/1078-0432.CCR-06-1570 10.1097/JTO.0b013e31820a3a6b 10.1038/sj.onc.1207813 10.1172/JCI65385 10.1371/journal.pone.0121323 10.1158/2159-8290.CD-16-0596 10.1158/1078-0432.CCR-14-2151 10.1038/nature00766 10.1038/nm.2644 10.1158/1541-7786.MCR-12-0652 10.1007/s00432-012-1328-6 10.1126/scitranslmed.3002003 10.1073/pnas.0710370104 10.1016/j.jtho.2015.12.107 10.1016/j.jtho.2017.01.023 10.1200/JCO.2012.45.6095 10.1016/0092-8674(85)90115-1 10.1371/journal.pone.0118210 10.1158/1541-7786.MCR-15-0506 10.1007/s10637-012-9912-9 10.1001/jama.2017.3438 10.1002/ijc.28475 10.1158/1078-0432.CCR-07-5123 10.1016/j.molonc.2015.11.007 10.1016/j.lungcan.2015.01.020 10.1073/pnas.1019559108 10.1097/JTO.0b013e3181e2138b 10.1002/cncr.20950 10.1016/j.cllc.2017.04.002 10.1016/S0021-9258(17)42099-0 10.18632/oncotarget.9137 10.18632/oncotarget.13069 10.18632/oncotarget.10458 10.1093/jnci/djx014 10.1158/1538-7445.AM10-4119 10.1200/jco.2013.31.15_suppl.8107 10.1158/1078-0432.CCR-15-0560 10.1200/jco.2017.35.18_suppl.lba9007 10.1038/nature13385 10.1200/jco.2013.31.15_suppl.8116
ContentType	Journal Article
Copyright	Springer Nature Limited 2017 COPYRIGHT 2017 Nature Publishing Group Copyright Nature Publishing Group Nov 2017
Copyright_xml	– notice: Springer Nature Limited 2017 – notice: COPYRIGHT 2017 Nature Publishing Group – notice: Copyright Nature Publishing Group Nov 2017
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7RV 7TK 7TM 7TO 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9- K9. KB0 LK8 M0R M0S M1P M7P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8
DOI	10.1038/nrc.2017.84
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Nursing & Allied Health Database Neurosciences Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Proquest Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Consumer Health Database ProQuest Health & Medical Collection Medical Database Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	ProQuest Central Student MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	1474-1768
EndPage	658
ExternalDocumentID	A511282576 29068003 10_1038_nrc_2017_84
Genre	Journal Article Review
GroupedDBID	--- .55 0R~ 123 29M 36B 39C 3V. 4.4 53G 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AAEEF AARCD AAWYQ AAYZH AAZLF ABAWZ ABDBF ABJNI ABLJU ABUWG ACGFS ACIWK ACPRK ACUHS ADBBV AENEX AFBBN AFKRA AFRAH AFSHS AGAYW AGHTU AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ARMCB ASPBG AVWKF AXYYD AZFZN AZQEC B0M BBNVY BENPR BHPHI BKEYQ BKKNO BKNYI BPHCQ BVXVI CCPQU CS3 DB5 EAD EAP EBS EE. EJD EMB EMK EMOBN EPL ESX EX3 EXGXG F5P FEDTE FQGFK FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IHR IHW INH INR ITC K9- L7B M0R M1P M7P N9A NAPCQ NNMJJ O9- ODYON PQQKQ PROAC PSQYO Q2X RIG RNR RNS RNT RNTTT SHXYY SIXXV SNYQT SOJ SV3 TAOOD TBHMF TDRGL TSG TUS UKHRP WOW X7M ~8M AAYXX ABFSG ACSTC AFANA AFFHD AGSTI ALPWD ATHPR CITATION PHGZM PHGZT PJZUB PPXIY PQGLB CGR CUY CVF ECM EIF NPM 7TK 7TM 7TO 7XB 8FD 8FE 8FH 8FK DWQXO FR3 GNUQQ H94 K9. LK8 P64 PKEHL PQEST PQUKI PRINS RC3 7X8
ID	FETCH-LOGICAL-c452t-5839a82ff868fedd1caac29d3df652c0b9012f6f0ae3ea963792426a54aa32bb3
IEDL.DBID	M7P
ISICitedReferencesCount	740
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000413667100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1474-175X 1474-1768
IngestDate	Sun Nov 09 09:43:41 EST 2025 Sun Nov 30 04:46:18 EST 2025 Tue Nov 11 10:44:04 EST 2025 Tue Nov 04 17:11:32 EST 2025 Thu May 22 21:23:23 EDT 2025 Mon Jul 21 06:05:59 EDT 2025 Sat Nov 29 02:52:25 EST 2025 Tue Nov 18 21:54:06 EST 2025 Fri Feb 21 02:37:19 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	11
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c452t-5839a82ff868fedd1caac29d3df652c0b9012f6f0ae3ea963792426a54aa32bb3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
PMID	29068003
PQID	1955646694
PQPubID	27578
PageCount	22
ParticipantIDs	proquest_miscellaneous_1955617679 proquest_journals_1955646694 gale_infotracmisc_A511282576 gale_infotracacademiconefile_A511282576 gale_healthsolutions_A511282576 pubmed_primary_29068003 crossref_citationtrail_10_1038_nrc_2017_84 crossref_primary_10_1038_nrc_2017_84 springer_journals_10_1038_nrc_2017_84
PublicationCentury	2000
PublicationDate	2017-11-01
PublicationDateYYYYMMDD	2017-11-01
PublicationDate_xml	– month: 11 year: 2017 text: 2017-11-01 day: 01
PublicationDecade	2010
PublicationPlace	London
PublicationPlace_xml	– name: London – name: England
PublicationTitle	Nature reviews. Cancer
PublicationTitleAbbrev	Nat Rev Cancer
PublicationTitleAlternate	Nat Rev Cancer
PublicationYear	2017
Publisher	Nature Publishing Group UK Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Nature Publishing Group
References	Wildemann (CR299) 2014; 32 Li (CR208) 2014; 20 Manchado (CR51) 2016; 534 Kris (CR2) 2014; 311 Cargnelutti (CR126) 2015; 6 Tamiya (CR252) 2017; 12 Tani (CR166) 2016; 15 Heist (CR105) 2016; 11 Ou (CR91) 2017; 108 Gainor (CR30) 2016; 6 CR159 Gower, Hsu, Hsu, Wang, Giaccone (CR200) 2016; 10 Yamaguchi (CR168) 2014; 83 Pao (CR80) 2005; 2 Terai (CR179) 2013; 11 Janne (CR316) 2016; 11 Mink (CR213) 2010; 8 Sos (CR129) 2009; 69 Bivona, Doebele (CR7) 2016; 22 Sasaki (CR102) 2010; 70 Ostrem, Peters, Sos, Wells, Shokat (CR60) 2013; 503 Oxnard (CR236) 2014; 20 de Bruin (CR119) 2014; 4 Gouji, Takashi, Mitsuhiro, Yukito (CR155) 2014; 9 Weickhardt (CR243) 2012; 7 Katayama (CR103) 2014; 20 Karachaliou (CR134) 2015; 5 Stephens (CR270) 2004; 431 Lito, Solomon, Li, Hansen, Rosen (CR59) 2016; 351 Yao (CR43) 2015; 28 Kane, Shapiro, Stokoe, Weiss (CR189) 1999; 9 Okimoto (CR47) 2016; 113 Kobayashi, Mitsudomi (CR286) 2016; 107 Vaishnavi (CR165) 2017; 77 Farago (CR284) 2015; 10 Liu (CR196) 2016; 7 Muz, de la Puente, Azab, Azab (CR222) 2015; 3 Planchard (CR44) 2016; 17 McCoach (CR86) 2016; 34 Soda (CR25) 2007; 448 Lin (CR117) 2014; 111 Ou, Tan, Yen, Soo (CR38) 2012; 12 Meza, Meernik, Jeon, Cote (CR1) 2015; 10 Ariyasu (CR261) 2017; 28 Wald (CR220) 2011; 141 Kancha, von Bubnoff, Peschel, Duyster (CR17) 2009; 15 Goldman (CR55) 2014; 35 CR256 Choe (CR211) 2015; 8 Marchetti (CR41) 2011; 29 Tang (CR262) 2014; 134 Takeuchi (CR278) 2012; 18 Liu, Lee (CR245) 2015; 4 Kobayashi (CR81) 2005; 352 Rikova (CR273) 2007; 131 Zandi, Larsen, Andersen, Stockhausen, Poulsen (CR285) 2007; 19 Rosell (CR312) 2017; 5 CR139 Kim (CR115) 2015; 10 Rosell (CR14) 2009; 361 Lin (CR53) 2015; 47 Onozato (CR67) 2009; 4 Shan, Arkhipov, Kim, Pan, Shaw (CR76) 2013; 110 Nelson-Taylor (CR161) 2017; 16 Tabara (CR170) 2012; 7 Kris (CR74) 2015; 26 Engelman (CR127) 2007; 316 Takezawa (CR172) 2012; 2 Yoshida (CR147) 2010; 101 Peschard (CR63) 2001; 8 Ohashi (CR118) 2012; 109 Eberlein (CR123) 2015; 75 Gold (CR148) 2014; 19 Litvak (CR42) 2014; 9 Watanabe (CR84) 2015; 21 Amato (CR180) 2016; 76 Kohno (CR276) 2012; 18 Moroishi, Hansen, Guan (CR190) 2015; 15 Abbosh (CR237) 2017; 545 Lee (CR18) 2015; 33 Yan (CR109) 2013; 31 Choi (CR85) 2010; 363 Togashi (CR249) 2010; 5 Gautschi (CR290) 2017; 35 Gautschi (CR279) 2012; 7 Wang (CR191) 2010; 101 Kosaka (CR75) 2017; 77 Tolcher (CR50) 2015; 21 Yun (CR82) 2008; 105 Bahcall (CR108) 2016; 6 CR240 Bergethon (CR37) 2012; 30 Mazieres (CR70) 2013; 31 Dong, Fernandez-Salas, Li, Wang (CR162) 2016; 18 De Greve (CR280) 2012; 76 Planchard (CR6) 2016; 17 Kodama (CR257) 2014; 74 Lara (CR176) 2004; 5 Byers (CR158) 2013; 19 Lee (CR144) 2014; 26 Matsubara (CR292) 2012; 7 Katayama (CR93) 2012; 4 Gatzemeier (CR178) 2004; 15 Jamal-Hanjani (CR232) 2017; 376 Chiba (CR100) 2017; 17 Frampton (CR61) 2015; 5 Zhao, Yang, Xu, Lu, Jian (CR149) 2017; 7 Chung (CR227) 2012; 131 Ou (CR152) 2017; 12 Walter (CR281) 2013; 3 Shou (CR140) 2016; 379 Lotti (CR215) 2013; 210 Zhao (CR251) 2013; 14 Mazieres (CR73) 2016; 27 Ballard (CR254) 2016; 22 Ma (CR271) 2005; 65 Bivona (CR9) 2011; 471 CR246 CR244 Zhou (CR3) 2011; 12 Drilon, Cappuzzo, Ou, Camidge (CR68) 2017; 12 Kanda (CR146) 2013; 73 Lovly (CR181) 2014; 20 Doebele (CR101) 2012; 18 Chatterjee (CR226) 2013; 123 Kogita (CR225) 2014; 45 Velcheti (CR291) 2017; 12 Lee (CR192) 2016; 474 Shaw (CR5) 2014; 371 Arcila (CR71) 2012; 18 Niederst (CR111) 2015; 21 Gainor (CR231) 2016; 22 Sorensen (CR235) 2014; 120 Ramalingam (CR241) 2016; 11 Bean (CR98) 2008; 14 Solomon (CR4) 2014; 371 Klughammer (CR24) 2016; 11 Armstrong (CR27) 2004; 23 Scaltriti, Elkabets, Baselga (CR156) 2016; 22 Deng (CR132) 2016; 11 Wood, Hensing, Malik, Salgia (CR57) 2016; 2 Ihle (CR133) 2005; 4 Yamada (CR12) 2012; 18 Lee (CR293) 2016; 7 Lin (CR34) 2016; 11 Crystal (CR125) 2014; 346 Wang (CR221) 2014; 70 Janne (CR303) 2014; 9 Greve (CR210) 2015; 15 Katayama (CR116) 2011; 108 Chang (CR216) 2017; 58 Bean (CR151) 2007; 104 CR26 Han (CR314) 2015; 75 Witta (CR202) 2006; 66 Cha, Cho, Kim, Lee, Shim (CR197) 2016; 11 Costa (CR255) 2011; 29 CR21 Drilon (CR282) 2013; 3 Ng (CR10) 2012; 18 Uchibori (CR112) 2017; 8 Cappuzzo, Bemis, Varella-Garcia (CR272) 2006; 354 Roskoski (CR77) 2013; 68 Rangachari (CR247) 2015; 88 Sundaresan (CR234) 2016; 22 Redig (CR298) 2016; 22 Zhang (CR185) 2017; 123 Kim (CR201) 2013; 7 Gettinger (CR33) 2016; 17 Park, Kim, Hong, Cho (CR306) 2017; 12 Riely (CR317) 2015; 33 Arteaga, Engelman (CR169) 2014; 25 Sequist (CR153) 2011; 29 Yao (CR203) 2010; 107 Ota (CR230) 2015; 21 Mok (CR16) 2017; 376 Drilon (CR96) 2016; 22 Lin, Riely, Shaw (CR28) 2017; 7 Costa (CR187) 2014; 20 Wang (CR214) 2009; 15 Lira (CR294) 2014; 16 Oxnard (CR302) 2015; 33 Ramirez (CR238) 2016; 7 Cappuzzo (CR66) 2009; 27 Subbiah, Hong, Meric-Bernstam (CR35) 2016; 113 Huang (CR87) 2016; 15 Li (CR110) 2017; 23 Heinmoller (CR171) 2003; 9 Tan (CR304) 2013; 31 McDermott (CR274) 2008; 68 Lipson (CR277) 2012; 18 Yasuda (CR20) 2013; 5 Akbay (CR229) 2013; 3 Jonsson (CR242) 2017; 7 Ju (CR289) 2012; 22 Shaw (CR114) 2016; 374 Chuang (CR72) 2017; 12 Yamauchi (CR219) 2011; 1 Hsu (CR193) 2016; 7 Shigematsu (CR287) 2005; 97 Niederst (CR198) 2015; 6 Hoffknecht (CR253) 2015; 10 Das (CR263) 1977; 74 Joshi, Rice, Liu, Miller, Belani (CR48) 2015; 10 Davies (CR268) 2002; 417 CR56 Yu (CR79) 2013; 19 Zhang (CR204) 2016; 7 Peters (CR36) 2017; 377 Kodama (CR295) 2014; 13 Gandino, Longati, Medico, Prat, Comoglio (CR62) 1994; 269 Sequist (CR78) 2011; 3 Song, Rawal, Nemeth, Haura (CR141) 2011; 10 Langer, Stephenson, Thor, Vangel, Johnson (CR177) 2004; 22 Cross (CR88) 2014; 4 Hrustanovic (CR124) 2015; 21 Johnson (CR32) 2014; 57 Hyman (CR45) 2015; 373 Lynch (CR269) 2004; 350 Camidge (CR69) 2014; 32 Nakano (CR264) 1984; 81 Engelman (CR297) 2008; 14 Jia (CR113) 2016; 534 Brahmer (CR275) 2010; 28 Watanabe (CR23) 2014; 9 Ou (CR106) 2017; 12 Tricker (CR120) 2015; 5 Blakely (CR137) 2015; 11 Jiang (CR195) 2016; 102 Deeken, Loscher (CR248) 2007; 13 Yu (CR22) 2014; 25 Dudnik (CR258) 2016; 26 Ercan (CR121) 2012; 2 Wu (CR154) 2014; 32 Yoshida (CR205) 2016; 11 Wakelee (CR308) 2017; 79 Togashi (CR250) 2012; 70 Neal (CR309) 2016; 17 Murakami (CR223) 2014; 9 Rho (CR260) 2017; 77 Yoshida (CR212) 2015; 21 Moran (CR315) 2014; 3 Hata (CR83) 2016; 22 Gomez (CR239) 2016; 17 Kim (CR52) 2016; 14 Gainor (CR95) 2016; 34 Zhang (CR31) 2016; 22 Kim, Kim, Lee, Shim (CR288) 2017; 12 Gandhi (CR136) 2017; 12 Janne (CR49) 2017; 317 Tiedt (CR301) 2011; 71 Paik (CR39) 2011; 29 An (CR217) 2013; 139 Kobayashi (CR199) 2013; 8 Gu (CR174) 2016; 9 Kawabata (CR135) 2014; 7 Zhang (CR157) 2012; 44 Trusolino, Bertotti, Comoglio (CR150) 2010; 11 Budha (CR13) 2012; 92 Wu, Li, Jang, Wang, Xiong (CR206) 2014; 7 Bae, Park, Hong, Lee, Lee (CR218) 2016; 6 Von Pawel (CR311) 2014; 32 Ludovini (CR128) 2011; 6 Jackman (CR259) 2013; 31 Hunter (CR58) 2014; 111 Balak (CR99) 2006; 12 Price (CR305) 2010; 5 Kosaka (CR300) 2006; 12 Morgillo, Woo, Kim, Hong, Lee (CR182) 2006; 66 Facchinetti (CR104) 2016; 22 Engelman (CR131) 2006; 116 Sequist (CR15) 2013; 31 Zhang (CR194) 2009; 11 Morris (CR267) 1994; 263 Stransky, Cerami, Schalm, Kim, Lengauer (CR296) 2014; 5 Drilon (CR64) 2016; 34 Paik (CR65) 2015; 5 Shen (CR130) 2016; 77 Imielinski (CR40) 2012; 150 Thress (CR90) 2015; 21 Dziadziuszko (CR183) 2016; 11 Kim (CR142) 2012; 11 Alam (CR11) 2010; 11 Wheeler, Iida, Dunn (CR145) 2009; 14 Yarden, Sliwkowski (CR19) 2001; 2 Tao (CR54) 2016; 22 Cui (CR107) 2014; 57 Yu (CR89) 2015; 1 Choi (CR228) 2015; 10 Vaishnavi (CR283) 2013; 19 Russo (CR97) 2016; 6 Haura (CR307) 2010; 28 Song (CR163) 2015; 21 Clamon (CR175) 2005; 103 Gong (CR184) 2007; 4 Taniguchi (CR167) 2017; 108 Tanimoto (CR186) 2016; 23 Awad (CR94) 2013; 368 Ho (CR122) 2017; 12 Suda (CR233) 2016; 91 Yu (CR143) 2017; 12 Davies (CR164) 2013; 8 Wilson (CR207) 2014; 5 Wu (CR8) 2008; 14 Sharma (CR209) 2010; 141 Lee (CR318) 2016; 34 Heuckmann (CR92) 2011; 17 Gao (CR138) 2016; 9 Tanizaki (CR173) 2012; 18 CR188 Takahashi, Ritz, Cooper (CR265) 1985; 42 Friboulet (CR29) 2014; 4 Wilson (CR160) 2015; 27 Zhang (CR46) 2015; 526 Minakata (CR224) 2012; 103 Ward (CR266) 1994; 48 Reguart (CR313) 2014; 84 Spigel (CR310) 2013; 31 R Roskoski Jr (BFnrc201784_CR77) 2013; 68 T Kosaka (BFnrc201784_CR300) 2006; 12 J Mazieres (BFnrc201784_CR70) 2013; 31 Y Zhao (BFnrc201784_CR149) 2017; 7 TK Sundaresan (BFnrc201784_CR234) 2016; 22 P Peschard (BFnrc201784_CR63) 2001; 8 GR Oxnard (BFnrc201784_CR302) 2015; 33 JF Gainor (BFnrc201784_CR30) 2016; 6 K Uchibori (BFnrc201784_CR112) 2017; 8 S Kobayashi (BFnrc201784_CR81) 2005; 352 H Choi (BFnrc201784_CR228) 2015; 10 TJ Lynch (BFnrc201784_CR269) 2004; 350 F Wu (BFnrc201784_CR206) 2014; 7 L Gandhi (BFnrc201784_CR136) 2017; 12 T Yoshida (BFnrc201784_CR212) 2015; 21 SI Ou (BFnrc201784_CR91) 2017; 108 R Rosell (BFnrc201784_CR14) 2009; 361 SM Kim (BFnrc201784_CR142) 2012; 11 M Imielinski (BFnrc201784_CR40) 2012; 150 BC Wildemann (BFnrc201784_CR299) 2014; 32 Y Yarden (BFnrc201784_CR19) 2001; 2 MJ Niederst (BFnrc201784_CR111) 2015; 21 H Yasuda (BFnrc201784_CR20) 2013; 5 AM Litvak (BFnrc201784_CR42) 2014; 9 DR Spigel (BFnrc201784_CR310) 2013; 31 J Gainor (BFnrc201784_CR95) 2016; 34 R Katayama (BFnrc201784_CR103) 2014; 20 JC Chuang (BFnrc201784_CR72) 2017; 12 J Shou (BFnrc201784_CR140) 2016; 379 JJ Lin (BFnrc201784_CR34) 2016; 11 QF Deng (BFnrc201784_CR132) 2016; 11 BFnrc201784_CR159 P Lito (BFnrc201784_CR59) 2016; 351 EB Haura (BFnrc201784_CR307) 2010; 28 Z Yao (BFnrc201784_CR43) 2015; 28 L Zhang (BFnrc201784_CR185) 2017; 123 JA Engelman (BFnrc201784_CR297) 2008; 14 KR Amato (BFnrc201784_CR180) 2016; 76 J Bean (BFnrc201784_CR98) 2008; 14 TM Kim (BFnrc201784_CR115) 2015; 10 PK Paik (BFnrc201784_CR39) 2011; 29 VD Jonsson (BFnrc201784_CR242) 2017; 7 BFnrc201784_CR56 YS Ju (BFnrc201784_CR289) 2012; 22 D Planchard (BFnrc201784_CR6) 2016; 17 JF Deeken (BFnrc201784_CR248) 2007; 13 ML Sos (BFnrc201784_CR129) 2009; 69 AO Walter (BFnrc201784_CR281) 2013; 3 R Rosell (BFnrc201784_CR312) 2017; 5 Y Jia (BFnrc201784_CR113) 2016; 534 TG Bivona (BFnrc201784_CR9) 2011; 471 A Song (BFnrc201784_CR163) 2015; 21 JK Rho (BFnrc201784_CR260) 2017; 77 PC Hsu (BFnrc201784_CR193) 2016; 7 L Friboulet (BFnrc201784_CR29) 2014; 4 RK Kancha (BFnrc201784_CR17) 2009; 15 R Zandi (BFnrc201784_CR285) 2007; 19 M Bahcall (BFnrc201784_CR108) 2016; 6 HR Kim (BFnrc201784_CR201) 2013; 7 M Russo (BFnrc201784_CR97) 2016; 6 EC de Bruin (BFnrc201784_CR119) 2014; 4 B Muz (BFnrc201784_CR222) 2015; 3 W Pao (BFnrc201784_CR80) 2005; 2 K Minakata (BFnrc201784_CR224) 2012; 103 X Dong (BFnrc201784_CR162) 2016; 18 EK Kim (BFnrc201784_CR288) 2017; 12 T Moroishi (BFnrc201784_CR190) 2015; 15 SR Mink (BFnrc201784_CR213) 2010; 8 GM Frampton (BFnrc201784_CR61) 2015; 5 FH Wilson (BFnrc201784_CR160) 2015; 27 AN Li (BFnrc201784_CR110) 2017; 23 AT Shaw (BFnrc201784_CR5) 2014; 371 CH Yun (BFnrc201784_CR82) 2008; 105 A Murakami (BFnrc201784_CR223) 2014; 9 BFnrc201784_CR188 A Kogita (BFnrc201784_CR225) 2014; 45 Y Gong (BFnrc201784_CR184) 2007; 4 F Cappuzzo (BFnrc201784_CR272) 2006; 354 K Bergethon (BFnrc201784_CR37) 2012; 30 J Jiang (BFnrc201784_CR195) 2016; 102 BS Sorensen (BFnrc201784_CR235) 2014; 120 HA Yu (BFnrc201784_CR89) 2015; 1 T Sasaki (BFnrc201784_CR102) 2010; 70 JM Heuckmann (BFnrc201784_CR92) 2011; 17 SK Nelson-Taylor (BFnrc201784_CR161) 2017; 16 Y Kobayashi (BFnrc201784_CR286) 2016; 107 K Takezawa (BFnrc201784_CR172) 2012; 2 M Watanabe (BFnrc201784_CR84) 2015; 21 HJ Lee (BFnrc201784_CR144) 2014; 26 SY Bae (BFnrc201784_CR218) 2016; 6 C Costa (BFnrc201784_CR187) 2014; 20 E Dudnik (BFnrc201784_CR258) 2016; 26 D Rangachari (BFnrc201784_CR247) 2015; 88 MS Lee (BFnrc201784_CR293) 2016; 7 K Takeuchi (BFnrc201784_CR278) 2012; 18 SI Ou (BFnrc201784_CR152) 2017; 12 M Chiba (BFnrc201784_CR100) 2017; 17 BFnrc201784_CR246 R Katayama (BFnrc201784_CR93) 2012; 4 FF Gu (BFnrc201784_CR174) 2016; 9 KA Gold (BFnrc201784_CR148) 2014; 19 M Liu (BFnrc201784_CR196) 2016; 7 K Suda (BFnrc201784_CR233) 2016; 91 C Abbosh (BFnrc201784_CR237) 2017; 545 JR Brahmer (BFnrc201784_CR275) 2010; 28 ME Arcila (BFnrc201784_CR71) 2012; 18 BFnrc201784_CR240 LV Sequist (BFnrc201784_CR78) 2011; 3 E Manchado (BFnrc201784_CR51) 2016; 534 BFnrc201784_CR244 RC Doebele (BFnrc201784_CR101) 2012; 18 L Li (BFnrc201784_CR208) 2014; 20 BJ Solomon (BFnrc201784_CR4) 2014; 371 S Kawabata (BFnrc201784_CR135) 2014; 7 ME Lira (BFnrc201784_CR294) 2014; 16 Y Kobayashi (BFnrc201784_CR199) 2013; 8 JY Han (BFnrc201784_CR314) 2015; 75 T Gouji (BFnrc201784_CR155) 2014; 9 T Kohno (BFnrc201784_CR276) 2012; 18 V Velcheti (BFnrc201784_CR291) 2017; 12 MG Kris (BFnrc201784_CR74) 2015; 26 PA Janne (BFnrc201784_CR49) 2017; 317 R Dziadziuszko (BFnrc201784_CR183) 2016; 11 HA Yu (BFnrc201784_CR143) 2017; 12 PA Janne (BFnrc201784_CR316) 2016; 11 JY Kim (BFnrc201784_CR52) 2016; 14 H Shen (BFnrc201784_CR130) 2016; 77 S Zhang (BFnrc201784_CR31) 2016; 22 KS Thress (BFnrc201784_CR90) 2015; 21 N Karachaliou (BFnrc201784_CR134) 2015; 5 A Vaishnavi (BFnrc201784_CR165) 2017; 77 A Drilon (BFnrc201784_CR282) 2013; 3 Y Wang (BFnrc201784_CR221) 2014; 70 CM Blakely (BFnrc201784_CR137) 2015; 11 A Tamiya (BFnrc201784_CR252) 2017; 12 CE McCoach (BFnrc201784_CR86) 2016; 34 D Jackman (BFnrc201784_CR259) 2013; 31 KP Ng (BFnrc201784_CR10) 2012; 18 AS Crystal (BFnrc201784_CR125) 2014; 346 Y-L Wu (BFnrc201784_CR154) 2014; 32 P Ballard (BFnrc201784_CR254) 2016; 22 BFnrc201784_CR256 BFnrc201784_CR139 JS Park (BFnrc201784_CR306) 2017; 12 JY Wu (BFnrc201784_CR8) 2008; 14 Y Togashi (BFnrc201784_CR249) 2010; 5 CC Ho (BFnrc201784_CR122) 2017; 12 TW Johnson (BFnrc201784_CR32) 2014; 57 G Greve (BFnrc201784_CR210) 2015; 15 P Hoffknecht (BFnrc201784_CR253) 2015; 10 V Subbiah (BFnrc201784_CR35) 2016; 113 SH Ou (BFnrc201784_CR38) 2012; 12 DB Costa (BFnrc201784_CR255) 2011; 29 HA Yu (BFnrc201784_CR79) 2013; 19 S Peters (BFnrc201784_CR36) 2017; 377 C Zhang (BFnrc201784_CR46) 2015; 526 RA Okimoto (BFnrc201784_CR47) 2016; 113 F Lotti (BFnrc201784_CR215) 2013; 210 EA Akbay (BFnrc201784_CR229) 2013; 3 N Yamaguchi (BFnrc201784_CR168) 2014; 83 MJ Niederst (BFnrc201784_CR198) 2015; 6 SC Tang (BFnrc201784_CR262) 2014; 134 SN Gettinger (BFnrc201784_CR33) 2016; 17 P Heinmoller (BFnrc201784_CR171) 2003; 9 O Gautschi (BFnrc201784_CR290) 2017; 35 M Cargnelutti (BFnrc201784_CR126) 2015; 6 V Ludovini (BFnrc201784_CR128) 2011; 6 T Tani (BFnrc201784_CR166) 2016; 15 R Ariyasu (BFnrc201784_CR261) 2017; 28 S Ramalingam (BFnrc201784_CR241) 2016; 11 WH Ward (BFnrc201784_CR266) 1994; 48 PA Janne (BFnrc201784_CR303) 2014; 9 PK Paik (BFnrc201784_CR65) 2015; 5 HA Yu (BFnrc201784_CR22) 2014; 25 H Shigematsu (BFnrc201784_CR287) 2005; 97 FT Chung (BFnrc201784_CR227) 2012; 131 J Goldman (BFnrc201784_CR55) 2014; 35 U Gatzemeier (BFnrc201784_CR178) 2004; 15 GR Oxnard (BFnrc201784_CR236) 2014; 20 PC Ma (BFnrc201784_CR271) 2005; 65 M Scaltriti (BFnrc201784_CR156) 2016; 22 L Trusolino (BFnrc201784_CR150) 2010; 11 K Rikova (BFnrc201784_CR273) 2007; 131 AE Drilon (BFnrc201784_CR64) 2016; 34 T Yoshida (BFnrc201784_CR205) 2016; 11 N Reguart (BFnrc201784_CR313) 2014; 84 RS Heist (BFnrc201784_CR105) 2016; 11 N Alam (BFnrc201784_CR11) 2010; 11 M Takahashi (BFnrc201784_CR265) 1985; 42 D Ercan (BFnrc201784_CR121) 2012; 2 LV Sequist (BFnrc201784_CR15) 2013; 31 A Drilon (BFnrc201784_CR96) 2016; 22 DR Camidge (BFnrc201784_CR69) 2014; 32 AJ Redig (BFnrc201784_CR298) 2016; 22 CJ Langer (BFnrc201784_CR177) 2004; 22 J An (BFnrc201784_CR217) 2013; 139 A Drilon (BFnrc201784_CR68) 2017; 12 KD Davies (BFnrc201784_CR164) 2013; 8 D Lipson (BFnrc201784_CR277) 2012; 18 SB Yan (BFnrc201784_CR109) 2013; 31 U McDermott (BFnrc201784_CR274) 2008; 68 DA Cross (BFnrc201784_CR88) 2014; 4 S Chatterjee (BFnrc201784_CR226) 2013; 123 F Facchinetti (BFnrc201784_CR104) 2016; 22 A Tanimoto (BFnrc201784_CR186) 2016; 23 O Wald (BFnrc201784_CR220) 2011; 141 T Kodama (BFnrc201784_CR295) 2014; 13 T Kosaka (BFnrc201784_CR75) 2017; 77 A Gower (BFnrc201784_CR200) 2016; 10 JA Engelman (BFnrc201784_CR127) 2007; 316 F Armstrong (BFnrc201784_CR27) 2004; 23 P Stephens (BFnrc201784_CR270) 2004; 431 NT Ihle (BFnrc201784_CR133) 2005; 4 C Zhou (BFnrc201784_CR3) 2011; 12 KA Price (BFnrc201784_CR305) 2010; 5 S Watanabe (BFnrc201784_CR23) 2014; 9 C Choe (BFnrc201784_CR211) 2015; 8 AT Shaw (BFnrc201784_CR114) 2016; 374 J Tanizaki (BFnrc201784_CR173) 2012; 18 JA Engelman (BFnrc201784_CR131) 2006; 116 CL Arteaga (BFnrc201784_CR169) 2014; 25 SV Sharma (BFnrc201784_CR209) 2010; 141 H Terai (BFnrc201784_CR179) 2013; 11 J Bean (BFnrc201784_CR151) 2007; 104 HA Wakelee (BFnrc201784_CR308) 2017; 79 R Onozato (BFnrc201784_CR67) 2009; 4 R Kanda (BFnrc201784_CR146) 2013; 73 M Das (BFnrc201784_CR263) 1977; 74 Z Zhang (BFnrc201784_CR157) 2012; 44 Q Huang (BFnrc201784_CR87) 2016; 15 S Liu (BFnrc201784_CR245) 2015; 4 Y Shan (BFnrc201784_CR76) 2013; 110 SI Ou (BFnrc201784_CR106) 2017; 12 DM Hyman (BFnrc201784_CR45) 2015; 373 H Chang (BFnrc201784_CR216) 2017; 58 AW Tolcher (BFnrc201784_CR50) 2015; 21 J Zhao (BFnrc201784_CR251) 2013; 14 JW Neal (BFnrc201784_CR309) 2016; 17 PN Lara Jr (BFnrc201784_CR176) 2004; 5 NR Budha (BFnrc201784_CR13) 2012; 92 Z Tao (BFnrc201784_CR54) 2016; 22 K Tabara (BFnrc201784_CR170) 2012; 7 CM Lovly (BFnrc201784_CR181) 2014; 20 TG Bivona (BFnrc201784_CR7) 2016; 22 W Wang (BFnrc201784_CR214) 2009; 15 F Morgillo (BFnrc201784_CR182) 2006; 66 DR Gomez (BFnrc201784_CR239) 2016; 17 MM Awad (BFnrc201784_CR94) 2013; 368 M Jamal-Hanjani (BFnrc201784_CR232) 2017; 376 N Stransky (BFnrc201784_CR296) 2014; 5 JM Ostrem (BFnrc201784_CR60) 2013; 503 MG Kris (BFnrc201784_CR2) 2014; 311 SE Witta (BFnrc201784_CR202) 2006; 66 DL Wheeler (BFnrc201784_CR145) 2009; 14 L Lin (BFnrc201784_CR117) 2014; 111 EM Tricker (BFnrc201784_CR120) 2015; 5 H Davies (BFnrc201784_CR268) 2002; 417 DS Tan (BFnrc201784_CR304) 2013; 31 Z Yao (BFnrc201784_CR203) 2010; 107 K Ohashi (BFnrc201784_CR118) 2012; 109 AJ Weickhardt (BFnrc201784_CR243) 2012; 7 T Kodama (BFnrc201784_CR257) 2014; 74 D Matsubara (BFnrc201784_CR292) 2012; 7 G Clamon (BFnrc201784_CR175) 2005; 103 T Moran (BFnrc201784_CR315) 2014; 3 B Klughammer (BFnrc201784_CR24) 2016; 11 JC Hunter (BFnrc201784_CR58) 2014; 111 R Meza (BFnrc201784_CR1) 2015; 10 SW Morris (BFnrc201784_CR267) 1994; 263 J De Greve (BFnrc201784_CR280) 2012; 76 MN Balak (BFnrc201784_CR99) 2006; 12 L Song (BFnrc201784_CR141) 2011; 10 A Marchetti (BFnrc201784_CR41) 2011; 29 T Yoshida (BFnrc201784_CR147) 2010; 101 G Riely (BFnrc201784_CR317) 2015; 33 T
References_xml	– volume: 19 start-page: 1469 year: 2013 end-page: 1472 ident: CR283 article-title: Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer publication-title: Nat. Med. doi: 10.1038/nm.3352 – volume: 5 start-page: 960 year: 2015 end-page: 971 ident: CR120 article-title: Combined EGFR/MEK inhibition prevents the emergence of resistance in EGFR mutant lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0063 – volume: 316 start-page: 1039 year: 2007 end-page: 1043 ident: CR127 article-title: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling publication-title: Science doi: 10.1126/science.1141478 – volume: 74 start-page: 2790 year: 1977 end-page: 2794 ident: CR263 article-title: Specific radiolabeling of a cell surface receptor for epidermal growth factor publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.74.7.2790 – volume: 12 start-page: 145 year: 2017 end-page: 151 ident: CR152 article-title: Phase I results from a study of crizotinib in combination with erlotinib in patients with advanced nonsquamous non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.09.131 – volume: 30 start-page: 863 year: 2012 end-page: 870 ident: CR37 article-title: ROS1 rearrangements define a unique molecular class of lung cancers publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.6345 – volume: 27 start-page: 397 year: 2015 end-page: 408 ident: CR160 article-title: A functional landscape of resistance to ALK inhibition in lung cancer publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.02.005 – volume: 22 start-page: 5130 year: 2016 end-page: 5140 ident: CR254 article-title: Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0399 – volume: 471 start-page: 523 year: 2011 end-page: 526 ident: CR9 article-title: FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR publication-title: Nature doi: 10.1038/nature09870 – volume: 15 start-page: 6630 year: 2009 end-page: 6638 ident: CR214 article-title: Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1001 – volume: 12 start-page: 735 year: 2011 end-page: 742 ident: CR3 article-title: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70184-X – volume: 371 start-page: 1963 year: 2014 end-page: 1971 ident: CR5 article-title: Crizotinib in ROS1-rearranged non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1406766 – volume: 11 start-page: 535 year: 2016 end-page: 542 ident: CR132 article-title: Integrin β1-mediated acquired gefitinib resistance in non-small cell lung cancer cells occurs via the phosphoinositide 3-kinase-dependent pathway publication-title: Oncol. Lett. doi: 10.3892/ol.2015.3945 – volume: 23 start-page: 3139 year: 2016 end-page: 3149 ident: CR186 article-title: Histone deacetylase 3 inhibition overcomes BIM deletion polymorphism-mediated osimertinib resistance in EGFR-mutant lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2271 – volume: 20 start-page: 2714 year: 2014 end-page: 2726 ident: CR208 article-title: Metformin sensitizes EGFR-TKI-resistant human lung cancer cells and through inhibition of IL-6 signaling and EMT reversal publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2613 – volume: 81 start-page: 71 year: 1984 end-page: 75 ident: CR264 article-title: Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.81.1.71 – volume: 27 start-page: 281 year: 2016 end-page: 286 ident: CR73 article-title: Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv573 – volume: 21 start-page: 3924 year: 2015 end-page: 3933 ident: CR111 article-title: The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies publication-title: Clin. Cancer Res. – volume: 3 start-page: 26 year: 2014 ident: CR315 article-title: Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial publication-title: Exp. Hematol. Oncol. doi: 10.1186/2162-3619-3-26 – volume: 7 start-page: 472 year: 2017 end-page: 476 ident: CR149 article-title: AZD0530 sensitizes drug-resistant ALK-positive lung cancer cells by inhibiting SRC signaling publication-title: FEBS Open Bio doi: 10.1002/2211-5463.12162 – volume: 545 start-page: 446 year: 2017 end-page: 451 ident: CR237 article-title: Phylogenetic ctDNA analysis depicts early stage lung cancer evolution publication-title: Nature doi: 10.1038/nature22364 – volume: 17 start-page: 1661 year: 2016 end-page: 1671 ident: CR309 article-title: Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30561-7 – volume: 503 start-page: 548 year: 2013 end-page: 551 ident: CR60 article-title: K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions publication-title: Nature doi: 10.1038/nature12796 – volume: 109 start-page: E2127 year: 2012 end-page: E2133 ident: CR118 article-title: Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1203530109 – volume: 11 start-page: 834 year: 2010 end-page: 848 ident: CR150 article-title: MET signalling: principles and functions in development, organ regeneration and cancer publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3012 – volume: 7 start-page: 137 year: 2017 end-page: 155 ident: CR28 article-title: Targeting ALK: precision medicine takes on drug resistance publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1123 – volume: 77 start-page: 2712 year: 2017 end-page: 2721 ident: CR75 article-title: Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-3404 – volume: 374 start-page: 54 year: 2016 end-page: 61 ident: CR114 article-title: Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1508887 – volume: 31 start-page: 8116 year: 2013 ident: CR259 article-title: Pulsed dosing of erlotinib for central nervous system progression in EGFR-mutant non-small cell lung cancer publication-title: J. Clin. Oncol. – volume: 28 start-page: 3167 year: 2010 end-page: 3175 ident: CR275 article-title: Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.26.7609 – volume: 12 start-page: e15 year: 2017 end-page: e16 ident: CR291 article-title: FRMD4A/RET: a novel RET oncogenic fusion variant in non-small cell lung carcinoma publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.274 – volume: 7 start-page: 36101 year: 2016 end-page: 36114 ident: CR293 article-title: Identification of a novel partner gene, KIAA1217, fused to RET: functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma publication-title: Oncotarget – volume: 76 start-page: 305 year: 2016 end-page: 318 ident: CR180 article-title: EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-0717 – volume: 11 start-page: S152 year: 2016 ident: CR241 article-title: LBA1_PR: Osimertinb as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts publication-title: J. Thorac. Oncol. doi: 10.1016/S1556-0864(16)30324-0 – volume: 5 start-page: 7328 year: 2014 end-page: 7341 ident: CR207 article-title: Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway inhibition publication-title: Oncotarget doi: 10.18632/oncotarget.2397 – volume: 131 start-page: E227 year: 2012 end-page: E235 ident: CR227 article-title: Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer publication-title: Int. J. Cancer doi: 10.1002/ijc.27403 – volume: 102 start-page: 101 year: 2016 end-page: 107 ident: CR195 article-title: Coexistence of p16/CDKN2A homozygous deletions and activating EGFR mutations in lung adenocarcinoma patients signifies a poor response to EGFR-TKIs publication-title: Lung Cancer doi: 10.1016/j.lungcan.2016.10.015 – volume: 10 start-page: 1736 year: 2015 end-page: 1744 ident: CR115 article-title: Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000688 – volume: 31 start-page: 8107 year: 2013 ident: CR304 article-title: A phase Ib safety and tolerability study of a pan class I PI3K inhibitor buparlisib (BKM120) and gefitinib in EGFR TKI-resistance NSCLC publication-title: J. Clin. Oncol. – volume: 376 start-page: 2109 year: 2017 end-page: 2121 ident: CR232 article-title: Tracking the evolution of non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1616288 – volume: 4 start-page: 120ra117 year: 2012 ident: CR93 article-title: Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3003316 – volume: 101 start-page: 1279 year: 2010 end-page: 1285 ident: CR191 article-title: Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2010.01511.x – volume: 26 start-page: 46 year: 2016 end-page: 49 ident: CR258 article-title: Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy publication-title: J. Clin. Neurosci. doi: 10.1016/j.jocn.2015.05.068 – volume: 20 start-page: 1027 year: 2014 end-page: 1034 ident: CR181 article-title: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer publication-title: Nat. Med. doi: 10.1038/nm.3667 – volume: 7 start-page: 84951 year: 2016 end-page: 84964 ident: CR196 article-title: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors publication-title: Oncotarget – volume: 7 start-page: 12231 year: 2016 ident: CR204 article-title: A genetic cell context-dependent role for ZEB1 in lung cancer publication-title: Nat. Commun. doi: 10.1038/ncomms12231 – volume: 8 start-page: e82236 year: 2013 ident: CR164 article-title: Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer publication-title: PLoS ONE doi: 10.1371/journal.pone.0082236 – volume: 77 start-page: 1200 year: 2017 end-page: 1211 ident: CR260 article-title: Superior efficacy and selectivity of novel small-molecule kinase inhibitors of T790M-mutant EGFR in preclinical models of lung cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2432 – volume: 35 start-page: 1403 year: 2017 end-page: 1410 ident: CR290 article-title: Targeting RET in patients with RET-rearranged lung cancers: results from the global, multicenter RET registry publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.70.9352 – volume: 15 start-page: 2521 year: 2016 end-page: 2529 ident: CR87 article-title: Preclinical modeling of KIF5B-RET fusion lung adenocarcinoma publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0258 – volume: 141 start-page: 1503 year: 2011 end-page: 1512 ident: CR220 article-title: Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: role in non-small cell lung cancer tumor proliferation publication-title: J. Thorac. Cardiovasc. Surg. doi: 10.1016/j.jtcvs.2010.11.056 – volume: 5 start-page: 1623 year: 2010 end-page: 1629 ident: CR305 article-title: Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181ec1531 – volume: 31 start-page: 4105 year: 2013 end-page: 4114 ident: CR310 article-title: Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.47.4189 – volume: 15 start-page: 73 year: 2015 end-page: 79 ident: CR190 article-title: The emerging roles of YAP and TAZ in cancer publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3876 – volume: 66 start-page: 944 year: 2006 end-page: 950 ident: CR202 article-title: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-1988 – volume: 22 start-page: 3148 year: 2016 end-page: 3156 ident: CR298 article-title: Clinical and molecular characteristics of NF1-mutant lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2377 – volume: 18 start-page: 4910 year: 2012 end-page: 4918 ident: CR71 article-title: Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0912 – volume: 12 start-page: 447 year: 2012 end-page: 456 ident: CR38 article-title: ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway publication-title: Expert Rev. Anticancer Ther. doi: 10.1586/era.12.17 – volume: 6 start-page: 36 year: 2016 end-page: 44 ident: CR97 article-title: Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0940 – volume: 32 start-page: 8001 year: 2014 ident: CR69 article-title: Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8001 – volume: 7 start-page: 44206 year: 2017 ident: CR242 article-title: Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution publication-title: Sci. Rep. doi: 10.1038/srep44206 – volume: 22 start-page: 122 year: 2016 end-page: 133 ident: CR54 article-title: Coadministration of trametinib and palbociclib radiosensitizes KRAS-mutant non-small cell lung cancers and publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0589 – volume: 11 start-page: 1242 year: 2016 end-page: 1245 ident: CR105 article-title: Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.06.013 – ident: CR139 – volume: 7 start-page: 1093 year: 2013 end-page: 1102 ident: CR201 article-title: Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2013.08.001 – volume: 25 start-page: 423 year: 2014 end-page: 428 ident: CR22 article-title: Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt573 – volume: 113 start-page: 13456 year: 2016 end-page: 13461 ident: CR47 article-title: Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1610456113 – volume: 9 start-page: 1669 year: 2014 end-page: 1674 ident: CR42 article-title: Clinical characteristics and course of 63 patients with BRAF mutant lung cancers publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000344 – volume: 29 start-page: e443 year: 2011 end-page: e445 ident: CR255 article-title: CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.1313 – volume: 28 start-page: 370 year: 2015 end-page: 383 ident: CR43 article-title: BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.08.001 – volume: 21 start-page: 1038 year: 2015 end-page: 1047 ident: CR124 article-title: RAS-MAPK dependence underlies a rational polytherapy strategy in EML4- ALK-positive lung cancer publication-title: Nat. Med. doi: 10.1038/nm.3930 – volume: 18 start-page: 162 year: 2016 end-page: 171 ident: CR162 article-title: Elucidation of resistance mechanisms to second-generation ALK inhibitors alectinib and ceritinib in non-small cell lung cancer cells publication-title: Neoplasia doi: 10.1016/j.neo.2016.02.001 – volume: 101 start-page: 167 year: 2010 end-page: 172 ident: CR147 article-title: Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2009.01368.x – volume: 11 start-page: 1444 year: 2009 ident: CR194 article-title: YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway publication-title: Nat. Cell Biol. doi: 10.1038/ncb1993 – volume: 4 start-page: 33 year: 2015 ident: CR245 article-title: An overview of the design and conduct of the BATTLE trials publication-title: Chin. Clin. Oncol. – volume: 8 start-page: 995 year: 2001 end-page: 1004 ident: CR63 article-title: Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein publication-title: Mol. Cell doi: 10.1016/S1097-2765(01)00378-1 – volume: 12 start-page: 137 year: 2017 end-page: 140 ident: CR106 article-title: Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.09.119 – volume: 92 start-page: 203 year: 2012 end-page: 213 ident: CR13 article-title: Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2012.73 – volume: 1 start-page: 823 year: 2011 end-page: 833 ident: CR219 article-title: N-Cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells publication-title: Am. J. Cancer Res. – volume: 21 start-page: 4014 year: 2015 end-page: 4021 ident: CR230 article-title: Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0016 – volume: 18 start-page: 1472 year: 2012 end-page: 1482 ident: CR101 article-title: Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-2906 – volume: 379 start-page: 124 year: 2016 end-page: 133 ident: CR140 article-title: Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.06.002 – volume: 22 start-page: 2351 year: 2016 end-page: 2358 ident: CR96 article-title: A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2013 – volume: 19 start-page: 279 year: 2013 end-page: 290 ident: CR158 article-title: An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1558 – volume: 4 start-page: 662 year: 2014 end-page: 673 ident: CR29 article-title: The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0846 – volume: 34 start-page: 9065 year: 2016 ident: CR86 article-title: Resistance mechanisms to targeted therapies in ROS1+and ALK+non-small cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9065 – volume: 16 start-page: 229 year: 2014 end-page: 243 ident: CR294 article-title: A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer publication-title: J. Mol. Diagn. doi: 10.1016/j.jmoldx.2013.11.007 – volume: 23 start-page: 4929 year: 2017 end-page: 4937 ident: CR110 article-title: Acquired MET Y1248H and D1246N mutations mediate resistance to MET inhibitors in non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-3273 – volume: 28 start-page: 1387 year: 2010 end-page: 1394 ident: CR307 article-title: Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.25.4029 – volume: 17 start-page: 1683 year: 2016 end-page: 1696 ident: CR33 article-title: Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30392-8 – volume: 15 start-page: 947 year: 2015 ident: CR210 article-title: The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells publication-title: BMC Cancer doi: 10.1186/s12885-015-1967-5 – volume: 108 start-page: 228 year: 2017 end-page: 231 ident: CR91 article-title: Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.04.003 – volume: 32 start-page: 8045 year: 2014 ident: CR311 article-title: Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs) publication-title: J. Clin. Oncol. Abstr. doi: 10.1200/jco.2014.32.15_suppl.8045 – volume: 3 start-page: 1355 year: 2013 end-page: 1363 ident: CR229 article-title: Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0310 – volume: 57 start-page: 4427 year: 2014 end-page: 4453 ident: CR107 article-title: Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress publication-title: J. Med. Chem. doi: 10.1021/jm401427c – volume: 4 start-page: 606 year: 2014 end-page: 619 ident: CR119 article-title: Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0741 – volume: 31 start-page: 3327 year: 2013 end-page: 3334 ident: CR15 article-title: Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.44.2806 – volume: 2 start-page: 805 year: 2016 end-page: 812 ident: CR57 article-title: Prognostic and predictive value in KRAS in non-small-cell lung cancer: a review publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2016.0405 – volume: 108 start-page: 53 year: 2017 end-page: 60 ident: CR167 article-title: Amphiregulin triggered epidermal growth factor receptor activation confers crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors publication-title: Cancer Sci. doi: 10.1111/cas.13111 – volume: 263 start-page: 1281 year: 1994 end-page: 1284 ident: CR267 article-title: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma publication-title: Science doi: 10.1126/science.8122112 – ident: CR21 – volume: 9 start-page: e27 year: 2014 end-page: e28 ident: CR155 article-title: Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000113 – volume: 15 start-page: 162 year: 2016 end-page: 171 ident: CR166 article-title: Activation of EGFR bypass signaling by TGFα overexpression induces acquired resistance to alectinib in ALK-translocated lung cancer cells publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-15-0084 – volume: 11 start-page: 2254 year: 2012 end-page: 2264 ident: CR142 article-title: Activation of IL-6R/JAK1/STAT3 signaling induces resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-12-0311 – volume: 77 start-page: 1 year: 2016 end-page: 6 ident: CR130 article-title: TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2015.10.018 – volume: 15 start-page: 19 year: 2004 end-page: 27 ident: CR178 article-title: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer publication-title: Ann. Oncol. doi: 10.1093/annonc/mdh031 – volume: 107 start-page: 15535 year: 2010 end-page: 15540 ident: CR203 article-title: TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1009472107 – volume: 18 start-page: 382 year: 2012 end-page: 384 ident: CR277 article-title: Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies publication-title: Nat. Med. doi: 10.1038/nm.2673 – volume: 3 start-page: 1404 year: 2013 end-page: 1415 ident: CR281 article-title: Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0314 – volume: 373 start-page: 726 year: 2015 end-page: 736 ident: CR45 article-title: Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1502309 – volume: 27 start-page: 1667 year: 2009 end-page: 1674 ident: CR66 article-title: Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.19.1635 – volume: 368 start-page: 2395 year: 2013 end-page: 2401 ident: CR94 article-title: Acquired resistance to crizotinib from a mutation in CD74-ROS1 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1215530 – volume: 377 start-page: 829 year: 2017 end-page: 838 ident: CR36 article-title: Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1704795 – volume: 47 start-page: 250 year: 2015 end-page: 256 ident: CR53 article-title: The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies publication-title: Nat. Genet. doi: 10.1038/ng.3218 – volume: 14 start-page: 188 year: 2013 end-page: 193 ident: CR251 article-title: Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2012.06.004 – ident: CR26 – volume: 19 start-page: 2240 year: 2013 end-page: 2247 ident: CR79 article-title: Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2246 – volume: 22 start-page: 5983 year: 2016 end-page: 5991 ident: CR104 article-title: Crizotinib-resistant ROS1 mutations reveal a predictive kinase inhibitor sensitivity model for ROS1- and ALK-rearranged lung cancers publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0917 – volume: 7 start-page: 1872 year: 2012 end-page: 1876 ident: CR292 article-title: Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line. LC-2/ad publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182721ed1 – volume: 22 start-page: 472 year: 2016 end-page: 478 ident: CR7 article-title: A framework for understanding and targeting residual disease in oncogene-driven solid cancers publication-title: Nat. Med. doi: 10.1038/nm.4091 – volume: 66 start-page: 10100 year: 2006 end-page: 10111 ident: CR182 article-title: Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-1684 – volume: 11 start-page: e55 year: 2016 end-page: e58 ident: CR197 article-title: Case of ALK-rearranged adenocarcinoma with small cell carcinoma-like transformation and resistance to crizotinib publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2015.12.097 – volume: 3 start-page: 83 year: 2015 end-page: 92 ident: CR222 article-title: The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy publication-title: Hypoxia doi: 10.2147/HP.S93413 – volume: 75 start-page: 475 year: 2015 end-page: 483 ident: CR314 article-title: Phase I/II study of gefitinib (Iressa ) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-014-2664-9 – volume: 526 start-page: 583 year: 2015 end-page: 586 ident: CR46 article-title: RAF inhibitors that evade paradoxical MAPK pathway activation publication-title: Nature doi: 10.1038/nature14982 – volume: 79 start-page: 923 year: 2017 end-page: 932 ident: CR308 article-title: A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-017-3283-z – volume: 10 start-page: 1187 year: 2015 end-page: 1201 ident: CR228 article-title: Transcriptome analysis of individual stromal cell populations identifies stroma-tumor crosstalk in mouse lung cancer model publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.01.040 – volume: 350 start-page: 2129 year: 2004 end-page: 2139 ident: CR269 article-title: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040938 – volume: 34 start-page: 9059 year: 2016 ident: CR318 article-title: Addition of HSP90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC: results of a randomized phase 2 study [abstract] publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9059 – volume: 1 start-page: 982 year: 2015 end-page: 984 ident: CR89 article-title: Acquired resistance of EGFR-mutant lung cancer to a T790M-specific EGFR inhibitor: emergence of a third mutation (C797S) in the EGFR tyrosine kinase domain publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.1066 – ident: CR188 – volume: 19 start-page: 2013 year: 2007 end-page: 2023 ident: CR285 article-title: Mechanisms for oncogenic activation of the epidermal growth factor receptor publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2007.06.023 – volume: 29 start-page: 3574 year: 2011 end-page: 3579 ident: CR41 article-title: Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.9638 – volume: 534 start-page: 129 year: 2016 end-page: 132 ident: CR113 article-title: Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors publication-title: Nature doi: 10.1038/nature17960 – volume: 57 start-page: 4720 year: 2014 end-page: 4744 ident: CR32 article-title: Discovery of (10R)-7-amino-12- fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17- tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]- benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations publication-title: J. Med. Chem. doi: 10.1021/jm500261q – volume: 363 start-page: 1734 year: 2010 end-page: 1739 ident: CR85 article-title: EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1007478 – volume: 5 start-page: 231 year: 2004 end-page: 236 ident: CR176 article-title: Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial publication-title: Clin. Lung Cancer doi: 10.3816/CLC.2004.n.004 – volume: 75 start-page: 2489 year: 2015 end-page: 2500 ident: CR123 article-title: Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on RAS signaling in preclinical models publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3167 – volume: 22 start-page: 262 year: 2016 end-page: 269 ident: CR83 article-title: Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition publication-title: Nat. Med. doi: 10.1038/nm.4040 – volume: 25 start-page: 282 year: 2014 end-page: 303 ident: CR169 article-title: ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.02.025 – volume: 474 start-page: 154 year: 2016 end-page: 160 ident: CR192 article-title: Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2016.04.089 – volume: 12 start-page: S1069 year: 2017 end-page: S1070 ident: CR306 article-title: P2.06-003 a phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant non-small cell lung cancer (NSCLC) progressed on EGFR-TKI publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.1496 – volume: 5 start-page: 216ra177 year: 2013 ident: CR20 article-title: Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3007205 – volume: 20 start-page: 5686 year: 2014 end-page: 5696 ident: CR103 article-title: Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1511 – volume: 22 start-page: 1103 year: 2016 end-page: 1110 ident: CR234 article-title: Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1031 – volume: 35 start-page: 8026 year: 2014 ident: CR55 article-title: Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8026 – volume: 17 start-page: 281 year: 2017 ident: CR100 article-title: Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A publication-title: BMC Cancer doi: 10.1186/s12885-017-3263-z – volume: 58 start-page: 9 year: 2017 end-page: 18 ident: CR216 article-title: EGF induced RET inhibitor resistance in CCDC6-RET lung cancer cells publication-title: Yonsei Med. J. doi: 10.3349/ymj.2017.58.1.9 – volume: 6 start-page: 1334 year: 2016 end-page: 1341 ident: CR108 article-title: Acquired METD1228V mutation and resistance to MET inhibition in lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-0686 – volume: 2 start-page: e73 year: 2005 ident: CR80 article-title: Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain publication-title: PLoS Med. doi: 10.1371/journal.pmed.0020073 – volume: 448 start-page: 561 year: 2007 end-page: 566 ident: CR25 article-title: Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer publication-title: Nature doi: 10.1038/nature05945 – volume: 17 start-page: 1672 year: 2016 end-page: 1682 ident: CR239 article-title: Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30532-0 – volume: 11 start-page: 737 year: 2016 end-page: 747 ident: CR316 article-title: Combined pan-HER and ALK/ROS1/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer: results of a phase I study publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.01.022 – volume: 7 start-page: e23 year: 2012 end-page: e24 ident: CR279 article-title: A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182629903 – volume: 111 start-page: E748 year: 2014 end-page: E757 ident: CR117 article-title: Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1320956111 – volume: 84 start-page: 161 year: 2014 end-page: 167 ident: CR313 article-title: Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.02.011 – volume: 9 start-page: 5238 year: 2003 end-page: 5243 ident: CR171 article-title: HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin publication-title: Clin. Cancer Res. – volume: 7 start-page: 1807 year: 2012 end-page: 1814 ident: CR243 article-title: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182745948 – volume: 18 start-page: 521 year: 2012 end-page: 528 ident: CR10 article-title: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer publication-title: Nat. Med. doi: 10.1038/nm.2713 – volume: 17 start-page: 642 year: 2016 end-page: 650 ident: CR44 article-title: Dabrafenib in patients with BRAF -positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial publication-title: Lancet. Oncol. doi: 10.1016/S1470-2045(16)00077-2 – volume: 69 start-page: 3256 year: 2009 end-page: 3261 ident: CR129 article-title: PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4055 – volume: 11 start-page: 98 year: 2015 end-page: 110 ident: CR137 article-title: NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.03.012 – volume: 34 start-page: 9072 year: 2016 ident: CR95 article-title: Frequency and spectrum of ROS1 resistance mutations in ROS1-positive lung cancer patients progressing on crizotinib publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9072 – volume: 6 start-page: 5182 year: 2015 end-page: 5194 ident: CR126 article-title: Activation of RAS family members confers resistance to ROS1 targeting drugs publication-title: Oncotarget doi: 10.18632/oncotarget.3311 – volume: 45 start-page: 1430 year: 2014 end-page: 1436 ident: CR225 article-title: Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition publication-title: Int. J. Oncol. doi: 10.3892/ijo.2014.2574 – volume: 4 start-page: 1046 year: 2014 end-page: 1061 ident: CR88 article-title: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-0337 – volume: 12 start-page: S358 year: 2017 end-page: S359 ident: CR136 article-title: MA04.02 neratinib ± temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.398 – volume: 105 start-page: 2070 year: 2008 end-page: 2075 ident: CR82 article-title: The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0709662105 – volume: 10 start-page: 156 year: 2015 end-page: 163 ident: CR253 article-title: Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000380 – volume: 5 start-page: 17499 year: 2015 ident: CR134 article-title: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer publication-title: Scientif. Rep. doi: 10.1038/srep17499 – volume: 123 start-page: 2927 year: 2017 end-page: 2935 ident: CR185 article-title: Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer publication-title: Cancer doi: 10.1002/cncr.30677 – volume: 141 start-page: 69 year: 2010 end-page: 80 ident: CR209 article-title: A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations publication-title: Cell doi: 10.1016/j.cell.2010.02.027 – volume: 8 start-page: 14768 year: 2017 ident: CR112 article-title: Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer publication-title: Nat. Commun. doi: 10.1038/ncomms14768 – volume: 8 start-page: 3665 year: 2015 end-page: 3678 ident: CR211 article-title: Crosstalk with cancer-associated fibroblasts induces resistance of non-small cell lung cancer cells to epidermal growth factor receptor tyrosine kinase inhibition publication-title: Onco Targets Ther. doi: 10.2147/OTT.S89659 – volume: 13 start-page: 2910 year: 2014 end-page: 2918 ident: CR295 article-title: Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-14-0274 – volume: 110 start-page: 7270 year: 2013 end-page: 7275 ident: CR76 article-title: Transitions to catalytically inactive conformations in EGFR kinase publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1220843110 – volume: 28 start-page: 565 year: 2017 end-page: 567 ident: CR261 article-title: Efficacy of bevacizumab and erlotinib combination for leptomeningeal carcinomatosis after failure of erlotinib publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000489 – volume: 107 start-page: 1179 year: 2016 end-page: 1186 ident: CR286 article-title: Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy publication-title: Cancer Sci. doi: 10.1111/cas.12996 – volume: 361 start-page: 958 year: 2009 end-page: 967 ident: CR14 article-title: Screening for epidermal growth factor receptor mutations in lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0904554 – volume: 21 start-page: 739 year: 2015 end-page: 748 ident: CR50 article-title: Antitumor activity in RAS-driven tumors by blocking AKT and MEK publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1901 – volume: 10 start-page: 481 year: 2011 end-page: 494 ident: CR141 article-title: JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-10-0502 – ident: CR256 – volume: 9 start-page: 601 year: 1999 end-page: 604 ident: CR189 article-title: Induction of NF-κB by the Akt/PKB kinase publication-title: Curr. Biol. doi: 10.1016/S0960-9822(99)80265-6 – volume: 20 start-page: 2001 year: 2014 end-page: 2010 ident: CR187 article-title: The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2233 – volume: 10 start-page: 1670 year: 2015 end-page: 1674 ident: CR284 article-title: Durable clinical response to entrectinib in NTRK1-rearranged non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/01.JTO.0000473485.38553.f0 – volume: 431 start-page: 525 year: 2004 end-page: 526 ident: CR270 article-title: Lung cancer: intragenic ERBB2 kinase mutations in tumours publication-title: Nature doi: 10.1038/431525b – volume: 113 start-page: E1419 year: 2016 end-page: E1420 ident: CR35 article-title: Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: bench to bedside report publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1522052113 – volume: 22 start-page: 4585 year: 2016 end-page: 4593 ident: CR231 article-title: EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-3101 – volume: 17 start-page: 7394 year: 2011 end-page: 7401 ident: CR92 article-title: ALK mutations conferring differential resistance to structurally diverse ALK inhibitors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1648 – volume: 9 start-page: ra33 year: 2016 ident: CR138 article-title: JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors publication-title: Sci. Signal. doi: 10.1126/scisignal.aac8460 – volume: 14 start-page: 7519 year: 2008 end-page: 7525 ident: CR98 article-title: Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-0151 – volume: 44 start-page: 852 year: 2012 end-page: 860 ident: CR157 article-title: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer publication-title: Nat. Genet. doi: 10.1038/ng.2330 – volume: 12 start-page: S273 year: 2017 ident: CR252 article-title: OA08.05 Efficacy and cerebrospinal fluid concentration of afatinib in NSCLC patients with EGFR mutation developing leptomeningeal carcinomatosis publication-title: J. Thorac. Oncol. Abstr. doi: 10.1016/j.jtho.2016.11.270 – volume: 2 start-page: 934 year: 2012 end-page: 947 ident: CR121 article-title: Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0103 – volume: 77 start-page: 3551 year: 2017 end-page: 3563 ident: CR165 article-title: EGFR mediates responses to small molecule drugs targeting oncogenic fusion kinases publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0109 – volume: 376 start-page: 629 year: 2017 end-page: 640 ident: CR16 article-title: Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1612674 – volume: 18 start-page: 378 year: 2012 end-page: 381 ident: CR278 article-title: RET, ROS1 and ALK fusions in lung cancer publication-title: Nat. Med. doi: 10.1038/nm.2658 – volume: 73 start-page: 6243 year: 2013 end-page: 6253 ident: CR146 article-title: Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-4502 – volume: 48 start-page: 659 year: 1994 end-page: 666 ident: CR266 article-title: Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(94)90042-6 – volume: 11 start-page: E1 year: 2010 end-page: E4 ident: CR11 article-title: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung publication-title: Clin. Lung Cancer doi: 10.3816/CLC.2010.n.046 – volume: 11 start-page: 2027 year: 2016 end-page: 2032 ident: CR34 article-title: Clinical activity of Alectinib in advanced RET-rearranged non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.08.126 – volume: 150 start-page: 1107 year: 2012 end-page: 1120 ident: CR40 article-title: Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing publication-title: Cell doi: 10.1016/j.cell.2012.08.029 – volume: 22 start-page: 436 year: 2012 end-page: 445 ident: CR289 article-title: A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing publication-title: Genome Res. doi: 10.1101/gr.133645.111 – volume: 97 start-page: 339 year: 2005 end-page: 346 ident: CR287 article-title: Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dji055 – volume: 6 start-page: 6377 year: 2015 ident: CR198 article-title: RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer publication-title: Nat. Commun. doi: 10.1038/ncomms7377 – volume: 8 start-page: e75 year: 2013 end-page: e78 ident: CR199 article-title: Transformation to sarcomatoid carcinoma in ALK-rearranged adenocarcinoma, which developed acquired resistance to crizotinib and received subsequent chemotherapies publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e318293d96f – volume: 19 start-page: 1040 year: 2014 end-page: 1041 ident: CR148 article-title: A phase I/II study combining erlotinib and dasatinib for non-small cell lung cancer publication-title: Oncologist doi: 10.1634/theoncologist.2014-0228 – volume: 210 start-page: 2851 year: 2013 end-page: 2872 ident: CR215 article-title: Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A publication-title: J. Exp. Med. doi: 10.1084/jem.20131195 – volume: 32 start-page: 8017 year: 2014 ident: CR154 article-title: Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: a single-arm phase lb/ll study publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8017 – volume: 16 start-page: 1623 year: 2017 end-page: 1633 ident: CR161 article-title: Resistance to RET-inhibition in RET-rearranged NSCLC is mediated by reactivation of RAS/MAPK signaling publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0008 – volume: 3 start-page: 630 year: 2013 end-page: 635 ident: CR282 article-title: Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0035 – volume: 131 start-page: 1190 year: 2007 end-page: 1203 ident: CR273 article-title: Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer publication-title: Cell doi: 10.1016/j.cell.2007.11.025 – volume: 269 start-page: 1815 year: 1994 end-page: 1820 ident: CR62 article-title: Phosphorylation of serine 985 negatively regulates the hepatocyte growth factor receptor kinase publication-title: J. Biol. Chem. – volume: 351 start-page: 604 year: 2016 end-page: 608 ident: CR59 article-title: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism publication-title: Science doi: 10.1126/science.aad6204 – volume: 8 start-page: 809 year: 2010 end-page: 820 ident: CR213 article-title: Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-09-0460 – volume: 22 start-page: 1180 year: 2004 end-page: 1187 ident: CR177 article-title: Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2004.04.105 – volume: 13 start-page: 1663 year: 2007 end-page: 1674 ident: CR248 article-title: The blood-brain barrier and cancer: transporters, treatment, and Trojan horses publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-2854 – volume: 12 start-page: 5764 year: 2006 end-page: 5769 ident: CR300 article-title: Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0714 – volume: 71 start-page: 5255 year: 2011 end-page: 5264 ident: CR301 article-title: A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-4433 – volume: 4 start-page: 5 year: 2009 end-page: 11 ident: CR67 article-title: Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181913e0e – volume: 11 start-page: 1273 year: 2016 end-page: 1281 ident: CR183 article-title: An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.04.001 – volume: 26 start-page: 207 year: 2014 end-page: 221 ident: CR144 article-title: Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.05.019 – volume: 21 start-page: 560 year: 2015 end-page: 562 ident: CR90 article-title: Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M publication-title: Nat. Med. doi: 10.1038/nm.3854 – volume: 4 start-page: 1349 year: 2005 end-page: 1357 ident: CR133 article-title: The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-05-0149 – volume: 111 start-page: 8895 year: 2014 end-page: 8900 ident: CR58 article-title: selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1404639111 – volume: 7 start-page: 6653 year: 2014 end-page: 6661 ident: CR206 article-title: The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma publication-title: Int. J. Clin. Exp. Pathol. – volume: 68 start-page: 3389 year: 2008 end-page: 3395 ident: CR274 article-title: Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-6186 – volume: 70 start-page: 10038 year: 2010 end-page: 10043 ident: CR102 article-title: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-2956 – volume: 346 start-page: 1480 year: 2014 end-page: 1486 ident: CR125 article-title: Patient-derived models of acquired resistance can identify effective drug combinations for cancer publication-title: Science doi: 10.1126/science.1254721 – volume: 352 start-page: 786 year: 2005 end-page: 792 ident: CR81 article-title: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044238 – volume: 7 start-page: 10690 year: 2016 ident: CR238 article-title: Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells publication-title: Nat. Commun. doi: 10.1038/ncomms10690 – volume: 4 start-page: e294 year: 2007 ident: CR184 article-title: Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas publication-title: PLoS Med. doi: 10.1371/journal.pmed.0040294 – volume: 14 start-page: 1351 year: 2008 end-page: 1356 ident: CR297 article-title: Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers publication-title: Nat. Med. doi: 10.1038/nm.1890 – volume: 33 start-page: 1958 year: 2015 end-page: 1965 ident: CR18 article-title: Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.1736 – volume: 14 start-page: 667 year: 2009 end-page: 678 ident: CR145 article-title: The role of Src in solid tumors publication-title: Oncologist doi: 10.1634/theoncologist.2009-0009 – ident: CR159 – volume: 103 start-page: 1946 year: 2012 end-page: 1954 ident: CR224 article-title: Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2012.02408.x – ident: CR244 – volume: 91 start-page: 36 year: 2016 end-page: 40 ident: CR233 article-title: Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2015.11.016 – volume: 116 start-page: 2695 year: 2006 end-page: 2706 ident: CR131 article-title: Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer publication-title: J. Clin. Invest. doi: 10.1172/JCI28656 – volume: 26 start-page: 1421 year: 2015 end-page: 1427 ident: CR74 article-title: Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv186 – volume: 68 start-page: 68 year: 2013 end-page: 94 ident: CR77 article-title: Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2012.11.007 – volume: 18 start-page: 3592 year: 2012 end-page: 3602 ident: CR12 article-title: Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-2972 – volume: 2 start-page: 922 year: 2012 end-page: 933 ident: CR172 article-title: HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFR mutation publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0108 – volume: 18 start-page: 6219 year: 2012 end-page: 6226 ident: CR173 article-title: Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0392 – volume: 5 start-page: 4846 year: 2014 ident: CR296 article-title: The landscape of kinase fusions in cancer publication-title: Nat. Commun. doi: 10.1038/ncomms5846 – volume: 83 start-page: 37 year: 2014 end-page: 43 ident: CR168 article-title: Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.09.019 – volume: 70 start-page: 399 year: 2012 end-page: 405 ident: CR250 article-title: Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-012-1929-4 – volume: 371 start-page: 2167 year: 2014 end-page: 2177 ident: CR4 article-title: First-line crizotinib versus chemotherapy in ALK-positive lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1408440 – volume: 15 start-page: 460 year: 2009 end-page: 467 ident: CR17 article-title: Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-1757 – volume: 9 start-page: 66 year: 2016 ident: CR174 article-title: Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-016-0296-8 – volume: 21 start-page: 642 year: 2015 end-page: 651 ident: CR212 article-title: Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-0846 – volume: 9 start-page: e86459 year: 2014 ident: CR223 article-title: Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor publication-title: PLoS ONE doi: 10.1371/journal.pone.0086459 – volume: 12 start-page: 567 year: 2017 end-page: 572 ident: CR122 article-title: Acquired BRAF V600E mutation as resistant mechanism after treatment with osimertinib publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.2231 – volume: 12 start-page: 102 year: 2017 end-page: 109 ident: CR143 article-title: A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.08.140 – volume: 7 start-page: e41017 year: 2012 ident: CR170 article-title: Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells publication-title: PLoS ONE doi: 10.1371/journal.pone.0041017 – ident: CR240 – volume: 32 start-page: 10018 year: 2014 ident: CR299 article-title: Phase I study of the MEK 1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.10018 – volume: 9 start-page: 189 year: 2014 end-page: 194 ident: CR23 article-title: Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000048 – volume: 76 start-page: 123 year: 2012 end-page: 127 ident: CR280 article-title: Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.01.008 – volume: 7 start-page: 51922 year: 2016 end-page: 51933 ident: CR193 article-title: YAP promotes erlotinib resistance in human non-small cell lung cancer cells publication-title: Oncotarget – volume: 6 start-page: 32258 year: 2016 ident: CR218 article-title: Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions publication-title: Scientif. Rep. doi: 10.1038/srep32258 – volume: 311 start-page: 1998 year: 2014 end-page: 2006 ident: CR2 article-title: Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs publication-title: JAMA doi: 10.1001/jama.2014.3741 – volume: 34 start-page: 108 year: 2016 ident: CR64 article-title: Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC) publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.108 – volume: 22 start-page: 1313 year: 2016 end-page: 1317 ident: CR156 article-title: Molecular pathways: AXL, a membrane receptor mediator of resistance to therapy publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1458 – volume: 534 start-page: 647 year: 2016 end-page: 651 ident: CR51 article-title: A combinatorial strategy for treating KRAS-mutant lung cancer publication-title: Nature doi: 10.1038/nature18600 – volume: 9 start-page: 316 year: 2014 end-page: 323 ident: CR303 article-title: Phase I safety and pharmacokinetic study of the PI3K/mTOR inhibitor SAR245409 (XL765) in combination with erlotinib in patients with advanced solid tumors publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000088 – volume: 17 start-page: 984 year: 2016 end-page: 993 ident: CR6 article-title: Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30146-2 – volume: 5 start-page: 435 year: 2017 end-page: 444 ident: CR312 article-title: Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(17)30129-7 – volume: 29 start-page: 3307 year: 2011 end-page: 3315 ident: CR153 article-title: Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.0570 – volume: 7 start-page: 1824 year: 2014 end-page: 1832 ident: CR135 article-title: Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M publication-title: Cell Rep. doi: 10.1016/j.celrep.2014.05.039 – volume: 120 start-page: 3896 year: 2014 end-page: 3901 ident: CR235 article-title: Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib publication-title: Cancer doi: 10.1002/cncr.28964 – volume: 33 start-page: 8064 year: 2015 ident: CR317 article-title: A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.8064 – volume: 5 start-page: 842 year: 2015 end-page: 849 ident: CR65 article-title: Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-1467 – volume: 12 start-page: 15 year: 2017 end-page: 26 ident: CR68 article-title: Targeting MET in lung cancer: will expectations finally be MET? publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.10.014 – volume: 74 start-page: 1023 year: 2014 end-page: 1028 ident: CR257 article-title: Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-014-2578-6 – volume: 20 start-page: 1698 year: 2014 end-page: 1705 ident: CR236 article-title: Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2482 – volume: 2 start-page: 127 year: 2001 end-page: 137 ident: CR19 article-title: Untangling the ErbB signalling network publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/35052073 – volume: 21 start-page: 2379 year: 2015 end-page: 2387 ident: CR163 article-title: Molecular changes associated with acquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1350 – volume: 22 start-page: 5527 year: 2016 end-page: 5538 ident: CR31 article-title: The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0569 – volume: 354 start-page: 2619 year: 2006 end-page: 2621 ident: CR272 article-title: HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc060020 – ident: CR246 – volume: 12 start-page: e0171280 year: 2017 ident: CR288 article-title: The frequency and clinical impact of HER2 alterations in lung adenocarcinoma publication-title: PLoS ONE doi: 10.1371/journal.pone.0171280 – volume: 5 start-page: 850 year: 2015 end-page: 859 ident: CR61 article-title: Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0285 – volume: 70 start-page: abstr. 4119 year: 2014 ident: CR221 article-title: Abstract 4119: Cytoplasmic location of CXCR4 is correlated to loss of EMT marker and activation of downstream signaling pathway in non-small cell lung cancer publication-title: Cancer Res. – volume: 65 start-page: 1479 year: 2005 end-page: 1488 ident: CR271 article-title: Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274and small interfering RNA in non-small cell lung cancer publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-2650 – volume: 11 start-page: e0147344 year: 2016 ident: CR205 article-title: ZEB1 mediates acquired resistance to the epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer publication-title: PLoS ONE doi: 10.1371/journal.pone.0147344 – volume: 29 start-page: 2046 year: 2011 end-page: 2051 ident: CR39 article-title: Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.33.1280 – volume: 33 start-page: abstr. 2509 year: 2015 ident: CR302 article-title: Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.2509 – volume: 12 start-page: 6494 year: 2006 end-page: 6501 ident: CR99 article-title: Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1570 – volume: 6 start-page: 707 year: 2011 end-page: 715 ident: CR128 article-title: Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e31820a3a6b – volume: 23 start-page: 6071 year: 2004 end-page: 6082 ident: CR27 article-title: Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells publication-title: Oncogene doi: 10.1038/sj.onc.1207813 – volume: 123 start-page: 1732 year: 2013 end-page: 1740 ident: CR226 article-title: Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer publication-title: J. Clin. Invest. doi: 10.1172/JCI65385 – volume: 10 start-page: e0121323 year: 2015 ident: CR1 article-title: Lung cancer incidence trends by gender, race and histology in the United States, 1973–2010 publication-title: PLoS ONE doi: 10.1371/journal.pone.0121323 – volume: 6 start-page: 1118 year: 2016 end-page: 1133 ident: CR30 article-title: Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-0596 – volume: 21 start-page: 3552 year: 2015 end-page: 3560 ident: CR84 article-title: Ultra-sensitive detection of the pretreatment EGFR T790M mutation in non-small cell lung cancer patients with an EGFR-activating mutation using droplet digital PCR publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2151 – volume: 417 start-page: 949 year: 2002 end-page: 954 ident: CR268 article-title: Mutations of the BRAF gene in human cancer publication-title: Nature doi: 10.1038/nature00766 – volume: 18 start-page: 375 year: 2012 end-page: 377 ident: CR276 article-title: KIF5B-RET fusions in lung adenocarcinoma publication-title: Nat. Med. doi: 10.1038/nm.2644 – volume: 11 start-page: 759 year: 2013 end-page: 767 ident: CR179 article-title: Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-12-0652 – volume: 139 start-page: 379 year: 2013 end-page: 388 ident: CR217 article-title: Significance of cancer-associated fibroblasts in the regulation of gene expression in the leading cells of invasive lung cancer publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-012-1328-6 – ident: CR56 – volume: 3 start-page: 75ra26 year: 2011 ident: CR78 article-title: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3002003 – volume: 104 start-page: 20932 year: 2007 end-page: 20937 ident: CR151 article-title: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0710370104 – volume: 11 start-page: 545 year: 2016 end-page: 555 ident: CR24 article-title: Examining treatment outcomes with erlotinib in patients with advanced non-small cell lung cancer whose tumors harbor uncommon EGFR mutations publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2015.12.107 – volume: 12 start-page: 833 year: 2017 end-page: 842 ident: CR72 article-title: ERBB2-mutated metastatic non-small cell lung cancer: response and resistance to targeted therapies publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2017.01.023 – volume: 31 start-page: 1997 year: 2013 end-page: 2003 ident: CR70 article-title: Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.45.6095 – volume: 42 start-page: 581 year: 1985 end-page: 588 ident: CR265 article-title: Activation of a novel human transforming gene, ret, by DNA rearrangement publication-title: Cell doi: 10.1016/0092-8674(85)90115-1 – volume: 10 start-page: e0118210 year: 2015 ident: CR48 article-title: Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer publication-title: PLoS ONE doi: 10.1371/journal.pone.0118210 – volume: 14 start-page: 1019 year: 2016 end-page: 1029 ident: CR52 article-title: Phosphoproteomics reveals MAPK inhibitors enhance MET- and EGFR-driven AKT signaling in KRAS-mutant lung cancer publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-15-0506 – volume: 31 start-page: 833 year: 2013 end-page: 844 ident: CR109 article-title: LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models publication-title: Invest. New Drugs doi: 10.1007/s10637-012-9912-9 – volume: 317 start-page: 1844 year: 2017 end-page: 1853 ident: CR49 article-title: Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with kras-mutant advanced non-small cell lung cancer: the SELECT-1 randomized clinical trial publication-title: JAMA doi: 10.1001/jama.2017.3438 – volume: 134 start-page: 1484 year: 2014 end-page: 1494 ident: CR262 article-title: Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar publication-title: Int. J. Cancer doi: 10.1002/ijc.28475 – volume: 14 start-page: 4877 year: 2008 end-page: 4882 ident: CR8 article-title: Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5123 – volume: 10 start-page: 601 year: 2016 end-page: 609 ident: CR200 article-title: EMT is associated with, but does not drive resistance to ALK inhibitors among EML4-ALK non-small cell lung cancer publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2015.11.007 – volume: 88 start-page: 108 year: 2015 end-page: 111 ident: CR247 article-title: Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers publication-title: Lung Cancer doi: 10.1016/j.lungcan.2015.01.020 – volume: 108 start-page: 7535 year: 2011 end-page: 7540 ident: CR116 article-title: Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1019559108 – volume: 5 start-page: 950 year: 2010 end-page: 955 ident: CR249 article-title: Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181e2138b – volume: 103 start-page: 1670 year: 2005 end-page: 1675 ident: CR175 article-title: Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B publication-title: Cancer doi: 10.1002/cncr.20950 – volume: 2 start-page: e73 year: 2005 ident: BFnrc201784_CR80 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0020073 – volume: 11 start-page: 98 year: 2015 ident: BFnrc201784_CR137 publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.03.012 – volume: 354 start-page: 2619 year: 2006 ident: BFnrc201784_CR272 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMc060020 – volume: 9 start-page: 1669 year: 2014 ident: BFnrc201784_CR42 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000344 – volume: 371 start-page: 2167 year: 2014 ident: BFnrc201784_CR4 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1408440 – volume: 11 start-page: 834 year: 2010 ident: BFnrc201784_CR150 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/nrm3012 – volume: 7 start-page: 1872 year: 2012 ident: BFnrc201784_CR292 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182721ed1 – volume: 77 start-page: 1 year: 2016 ident: BFnrc201784_CR130 publication-title: Biomed. Pharmacother. doi: 10.1016/j.biopha.2015.10.018 – volume: 29 start-page: 3307 year: 2011 ident: BFnrc201784_CR153 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.0570 – volume: 9 start-page: 66 year: 2016 ident: BFnrc201784_CR174 publication-title: J. Hematol. Oncol. doi: 10.1186/s13045-016-0296-8 – volume: 9 start-page: 189 year: 2014 ident: BFnrc201784_CR23 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000048 – volume: 74 start-page: 2790 year: 1977 ident: BFnrc201784_CR263 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.74.7.2790 – volume: 19 start-page: 279 year: 2013 ident: BFnrc201784_CR158 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-1558 – volume: 12 start-page: 145 year: 2017 ident: BFnrc201784_CR152 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.09.131 – volume: 30 start-page: 863 year: 2012 ident: BFnrc201784_CR37 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.6345 – volume: 21 start-page: 560 year: 2015 ident: BFnrc201784_CR90 publication-title: Nat. Med. doi: 10.1038/nm.3854 – volume: 123 start-page: 1732 year: 2013 ident: BFnrc201784_CR226 publication-title: J. Clin. Invest. doi: 10.1172/JCI65385 – volume: 33 start-page: 8064 year: 2015 ident: BFnrc201784_CR317 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.8064 – volume: 12 start-page: S273 year: 2017 ident: BFnrc201784_CR252 publication-title: J. Thorac. Oncol. Abstr. doi: 10.1016/j.jtho.2016.11.270 – volume: 346 start-page: 1480 year: 2014 ident: BFnrc201784_CR125 publication-title: Science doi: 10.1126/science.1254721 – volume: 91 start-page: 36 year: 2016 ident: BFnrc201784_CR233 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2015.11.016 – volume: 104 start-page: 20932 year: 2007 ident: BFnrc201784_CR151 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0710370104 – volume: 14 start-page: 188 year: 2013 ident: BFnrc201784_CR251 publication-title: Clin. Lung Cancer doi: 10.1016/j.cllc.2012.06.004 – volume: 12 start-page: 735 year: 2011 ident: BFnrc201784_CR3 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(11)70184-X – volume: 350 start-page: 2129 year: 2004 ident: BFnrc201784_CR269 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa040938 – volume: 12 start-page: 6494 year: 2006 ident: BFnrc201784_CR99 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-1570 – volume: 11 start-page: 545 year: 2016 ident: BFnrc201784_CR24 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2015.12.107 – volume: 4 start-page: 5 year: 2009 ident: BFnrc201784_CR67 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181913e0e – volume: 103 start-page: 1946 year: 2012 ident: BFnrc201784_CR224 publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2012.02408.x – volume: 6 start-page: 1118 year: 2016 ident: BFnrc201784_CR30 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-0596 – volume: 22 start-page: 1180 year: 2004 ident: BFnrc201784_CR177 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2004.04.105 – volume: 76 start-page: 305 year: 2016 ident: BFnrc201784_CR180 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-15-0717 – volume: 3 start-page: 630 year: 2013 ident: BFnrc201784_CR282 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0035 – volume: 20 start-page: 2714 year: 2014 ident: BFnrc201784_CR208 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2613 – volume: 22 start-page: 122 year: 2016 ident: BFnrc201784_CR54 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0589 – volume: 28 start-page: 370 year: 2015 ident: BFnrc201784_CR43 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.08.001 – volume: 11 start-page: 1242 year: 2016 ident: BFnrc201784_CR105 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.06.013 – volume: 526 start-page: 583 year: 2015 ident: BFnrc201784_CR46 publication-title: Nature doi: 10.1038/nature14982 – volume: 12 start-page: 137 year: 2017 ident: BFnrc201784_CR106 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.09.119 – volume: 18 start-page: 3592 year: 2012 ident: BFnrc201784_CR12 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-2972 – volume: 28 start-page: 1387 year: 2010 ident: BFnrc201784_CR307 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.25.4029 – volume: 316 start-page: 1039 year: 2007 ident: BFnrc201784_CR127 publication-title: Science doi: 10.1126/science.1141478 – volume: 7 start-page: 44206 year: 2017 ident: BFnrc201784_CR242 publication-title: Sci. Rep. doi: 10.1038/srep44206 – volume: 5 start-page: 4846 year: 2014 ident: BFnrc201784_CR296 publication-title: Nat. Commun. doi: 10.1038/ncomms5846 – ident: BFnrc201784_CR244 doi: 10.1016/j.cllc.2017.04.002 – volume: 10 start-page: 1670 year: 2015 ident: BFnrc201784_CR284 publication-title: J. Thorac. Oncol. doi: 10.1097/01.JTO.0000473485.38553.f0 – volume: 368 start-page: 2395 year: 2013 ident: BFnrc201784_CR94 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1215530 – volume: 15 start-page: 2521 year: 2016 ident: BFnrc201784_CR87 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0258 – volume: 31 start-page: 833 year: 2013 ident: BFnrc201784_CR109 publication-title: Invest. New Drugs doi: 10.1007/s10637-012-9912-9 – volume: 11 start-page: 2254 year: 2012 ident: BFnrc201784_CR142 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-12-0311 – volume: 22 start-page: 2351 year: 2016 ident: BFnrc201784_CR96 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2013 – volume: 9 start-page: e27 year: 2014 ident: BFnrc201784_CR155 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000113 – volume: 77 start-page: 3551 year: 2017 ident: BFnrc201784_CR165 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0109 – volume: 3 start-page: 83 year: 2015 ident: BFnrc201784_CR222 publication-title: Hypoxia doi: 10.2147/HP.S93413 – volume: 363 start-page: 1734 year: 2010 ident: BFnrc201784_CR85 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1007478 – volume: 503 start-page: 548 year: 2013 ident: BFnrc201784_CR60 publication-title: Nature doi: 10.1038/nature12796 – volume: 81 start-page: 71 year: 1984 ident: BFnrc201784_CR264 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.81.1.71 – volume: 7 start-page: 12231 year: 2016 ident: BFnrc201784_CR204 publication-title: Nat. Commun. doi: 10.1038/ncomms12231 – volume: 8 start-page: 14768 year: 2017 ident: BFnrc201784_CR112 publication-title: Nat. Commun. doi: 10.1038/ncomms14768 – volume: 9 start-page: ra33 year: 2016 ident: BFnrc201784_CR138 publication-title: Sci. Signal. doi: 10.1126/scisignal.aac8460 – volume: 5 start-page: 17499 year: 2015 ident: BFnrc201784_CR134 publication-title: Scientif. Rep. doi: 10.1038/srep17499 – volume: 269 start-page: 1815 year: 1994 ident: BFnrc201784_CR62 publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(17)42099-0 – volume: 66 start-page: 10100 year: 2006 ident: BFnrc201784_CR182 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-06-1684 – volume: 14 start-page: 7519 year: 2008 ident: BFnrc201784_CR98 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-0151 – volume: 11 start-page: e55 year: 2016 ident: BFnrc201784_CR197 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2015.12.097 – volume: 17 start-page: 642 year: 2016 ident: BFnrc201784_CR44 publication-title: Lancet. Oncol. doi: 10.1016/S1470-2045(16)00077-2 – volume: 116 start-page: 2695 year: 2006 ident: BFnrc201784_CR131 publication-title: J. Clin. Invest. doi: 10.1172/JCI28656 – volume: 27 start-page: 397 year: 2015 ident: BFnrc201784_CR160 publication-title: Cancer Cell doi: 10.1016/j.ccell.2015.02.005 – volume: 15 start-page: 73 year: 2015 ident: BFnrc201784_CR190 publication-title: Nat. Rev. Cancer doi: 10.1038/nrc3876 – volume: 12 start-page: 5764 year: 2006 ident: BFnrc201784_CR300 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-0714 – volume: 18 start-page: 4910 year: 2012 ident: BFnrc201784_CR71 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0912 – volume: 11 start-page: e0147344 year: 2016 ident: BFnrc201784_CR205 publication-title: PLoS ONE doi: 10.1371/journal.pone.0147344 – volume: 113 start-page: 13456 year: 2016 ident: BFnrc201784_CR47 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1610456113 – volume: 44 start-page: 852 year: 2012 ident: BFnrc201784_CR157 publication-title: Nat. Genet. doi: 10.1038/ng.2330 – volume: 5 start-page: 435 year: 2017 ident: BFnrc201784_CR312 publication-title: Lancet Respir. Med. doi: 10.1016/S2213-2600(17)30129-7 – volume: 77 start-page: 1200 year: 2017 ident: BFnrc201784_CR260 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-2432 – volume: 34 start-page: 9059 year: 2016 ident: BFnrc201784_CR318 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9059 – volume: 379 start-page: 124 year: 2016 ident: BFnrc201784_CR140 publication-title: Cancer Lett. doi: 10.1016/j.canlet.2016.06.002 – volume: 92 start-page: 203 year: 2012 ident: BFnrc201784_CR13 publication-title: Clin. Pharmacol. Ther. doi: 10.1038/clpt.2012.73 – volume: 21 start-page: 739 year: 2015 ident: BFnrc201784_CR50 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1901 – volume: 448 start-page: 561 year: 2007 ident: BFnrc201784_CR25 publication-title: Nature doi: 10.1038/nature05945 – volume: 7 start-page: 36101 year: 2016 ident: BFnrc201784_CR293 publication-title: Oncotarget doi: 10.18632/oncotarget.9137 – volume: 12 start-page: e15 year: 2017 ident: BFnrc201784_CR291 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.274 – volume: 101 start-page: 167 year: 2010 ident: BFnrc201784_CR147 publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2009.01368.x – volume: 25 start-page: 423 year: 2014 ident: BFnrc201784_CR22 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdt573 – volume: 102 start-page: 101 year: 2016 ident: BFnrc201784_CR195 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2016.10.015 – volume: 32 start-page: 10018 year: 2014 ident: BFnrc201784_CR299 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.10018 – volume: 21 start-page: 3552 year: 2015 ident: BFnrc201784_CR84 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-2151 – volume: 6 start-page: 1334 year: 2016 ident: BFnrc201784_CR108 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-0686 – volume: 7 start-page: 84951 year: 2016 ident: BFnrc201784_CR196 publication-title: Oncotarget doi: 10.18632/oncotarget.13069 – volume: 3 start-page: 26 year: 2014 ident: BFnrc201784_CR315 publication-title: Exp. Hematol. Oncol. doi: 10.1186/2162-3619-3-26 – volume: 88 start-page: 108 year: 2015 ident: BFnrc201784_CR247 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2015.01.020 – volume: 15 start-page: 947 year: 2015 ident: BFnrc201784_CR210 publication-title: BMC Cancer doi: 10.1186/s12885-015-1967-5 – volume: 2 start-page: 922 year: 2012 ident: BFnrc201784_CR172 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0108 – volume: 57 start-page: 4720 year: 2014 ident: BFnrc201784_CR32 publication-title: J. Med. Chem. doi: 10.1021/jm500261q – volume: 12 start-page: 567 year: 2017 ident: BFnrc201784_CR122 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.2231 – volume: 3 start-page: 1404 year: 2013 ident: BFnrc201784_CR281 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0314 – volume: 21 start-page: 2379 year: 2015 ident: BFnrc201784_CR163 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1350 – volume: 9 start-page: 316 year: 2014 ident: BFnrc201784_CR303 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000088 – volume: 1 start-page: 823 year: 2011 ident: BFnrc201784_CR219 publication-title: Am. J. Cancer Res. – volume: 32 start-page: 8045 year: 2014 ident: BFnrc201784_CR311 publication-title: J. Clin. Oncol. Abstr. doi: 10.1200/jco.2014.32.15_suppl.8045 – volume: 2 start-page: 805 year: 2016 ident: BFnrc201784_CR57 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2016.0405 – volume: 65 start-page: 1479 year: 2005 ident: BFnrc201784_CR271 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-04-2650 – volume: 11 start-page: E1 year: 2010 ident: BFnrc201784_CR11 publication-title: Clin. Lung Cancer doi: 10.3816/CLC.2010.n.046 – volume: 13 start-page: 1663 year: 2007 ident: BFnrc201784_CR248 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-06-2854 – volume: 109 start-page: E2127 year: 2012 ident: BFnrc201784_CR118 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1203530109 – volume: 19 start-page: 2240 year: 2013 ident: BFnrc201784_CR79 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-2246 – volume: 23 start-page: 3139 year: 2016 ident: BFnrc201784_CR186 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-2271 – volume: 7 start-page: 51922 year: 2016 ident: BFnrc201784_CR193 publication-title: Oncotarget doi: 10.18632/oncotarget.10458 – volume: 26 start-page: 46 year: 2016 ident: BFnrc201784_CR258 publication-title: J. Clin. Neurosci. doi: 10.1016/j.jocn.2015.05.068 – volume: 17 start-page: 984 year: 2016 ident: BFnrc201784_CR6 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30146-2 – volume: 22 start-page: 436 year: 2012 ident: BFnrc201784_CR289 publication-title: Genome Res. doi: 10.1101/gr.133645.111 – volume: 16 start-page: 1623 year: 2017 ident: BFnrc201784_CR161 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-17-0008 – volume: 417 start-page: 949 year: 2002 ident: BFnrc201784_CR268 publication-title: Nature doi: 10.1038/nature00766 – volume: 12 start-page: e0171280 year: 2017 ident: BFnrc201784_CR288 publication-title: PLoS ONE doi: 10.1371/journal.pone.0171280 – ident: BFnrc201784_CR139 doi: 10.1093/jnci/djx014 – volume: 70 start-page: abstr. 4119 year: 2014 ident: BFnrc201784_CR221 publication-title: Cancer Res. doi: 10.1158/1538-7445.AM10-4119 – volume: 17 start-page: 1683 year: 2016 ident: BFnrc201784_CR33 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30392-8 – volume: 14 start-page: 667 year: 2009 ident: BFnrc201784_CR145 publication-title: Oncologist doi: 10.1634/theoncologist.2009-0009 – volume: 545 start-page: 446 year: 2017 ident: BFnrc201784_CR237 publication-title: Nature doi: 10.1038/nature22364 – volume: 34 start-page: 9072 year: 2016 ident: BFnrc201784_CR95 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9072 – volume: 68 start-page: 3389 year: 2008 ident: BFnrc201784_CR274 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-07-6186 – volume: 57 start-page: 4427 year: 2014 ident: BFnrc201784_CR107 publication-title: J. Med. Chem. doi: 10.1021/jm401427c – volume: 73 start-page: 6243 year: 2013 ident: BFnrc201784_CR146 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-12-4502 – volume: 31 start-page: 8107 year: 2013 ident: BFnrc201784_CR304 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2013.31.15_suppl.8107 – volume: 15 start-page: 162 year: 2016 ident: BFnrc201784_CR166 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-15-0084 – volume: 18 start-page: 375 year: 2012 ident: BFnrc201784_CR276 publication-title: Nat. Med. doi: 10.1038/nm.2644 – volume: 34 start-page: 9065 year: 2016 ident: BFnrc201784_CR86 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.9065 – volume: 5 start-page: 842 year: 2015 ident: BFnrc201784_CR65 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-1467 – volume: 18 start-page: 382 year: 2012 ident: BFnrc201784_CR277 publication-title: Nat. Med. doi: 10.1038/nm.2673 – volume: 110 start-page: 7270 year: 2013 ident: BFnrc201784_CR76 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1220843110 – volume: 22 start-page: 1103 year: 2016 ident: BFnrc201784_CR234 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1031 – volume: 18 start-page: 162 year: 2016 ident: BFnrc201784_CR162 publication-title: Neoplasia doi: 10.1016/j.neo.2016.02.001 – volume: 263 start-page: 1281 year: 1994 ident: BFnrc201784_CR267 publication-title: Science doi: 10.1126/science.8122112 – volume: 6 start-page: 5182 year: 2015 ident: BFnrc201784_CR126 publication-title: Oncotarget doi: 10.18632/oncotarget.3311 – volume: 7 start-page: 1093 year: 2013 ident: BFnrc201784_CR201 publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2013.08.001 – volume: 28 start-page: 3167 year: 2010 ident: BFnrc201784_CR275 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2009.26.7609 – volume: 75 start-page: 2489 year: 2015 ident: BFnrc201784_CR123 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-14-3167 – volume: 48 start-page: 659 year: 1994 ident: BFnrc201784_CR266 publication-title: Biochem. Pharmacol. doi: 10.1016/0006-2952(94)90042-6 – volume: 1 start-page: 982 year: 2015 ident: BFnrc201784_CR89 publication-title: JAMA Oncol. doi: 10.1001/jamaoncol.2015.1066 – volume: 7 start-page: 472 year: 2017 ident: BFnrc201784_CR149 publication-title: FEBS Open Bio doi: 10.1002/2211-5463.12162 – volume: 76 start-page: 123 year: 2012 ident: BFnrc201784_CR280 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2012.01.008 – volume: 107 start-page: 15535 year: 2010 ident: BFnrc201784_CR203 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1009472107 – volume: 20 start-page: 5686 year: 2014 ident: BFnrc201784_CR103 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-1511 – volume: 21 start-page: 3924 year: 2015 ident: BFnrc201784_CR111 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0560 – volume: 31 start-page: 4105 year: 2013 ident: BFnrc201784_CR310 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.47.4189 – volume: 6 start-page: 707 year: 2011 ident: BFnrc201784_CR128 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e31820a3a6b – volume: 317 start-page: 1844 year: 2017 ident: BFnrc201784_CR49 publication-title: JAMA doi: 10.1001/jama.2017.3438 – volume: 18 start-page: 521 year: 2012 ident: BFnrc201784_CR10 publication-title: Nat. Med. doi: 10.1038/nm.2713 – volume: 26 start-page: 207 year: 2014 ident: BFnrc201784_CR144 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.05.019 – volume: 32 start-page: 8017 year: 2014 ident: BFnrc201784_CR154 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8017 – volume: 5 start-page: 216ra177 year: 2013 ident: BFnrc201784_CR20 publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3007205 – volume: 5 start-page: 1623 year: 2010 ident: BFnrc201784_CR305 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181ec1531 – volume: 351 start-page: 604 year: 2016 ident: BFnrc201784_CR59 publication-title: Science doi: 10.1126/science.aad6204 – volume: 534 start-page: 129 year: 2016 ident: BFnrc201784_CR113 publication-title: Nature doi: 10.1038/nature17960 – volume: 311 start-page: 1998 year: 2014 ident: BFnrc201784_CR2 publication-title: JAMA doi: 10.1001/jama.2014.3741 – ident: BFnrc201784_CR56 – ident: BFnrc201784_CR240 doi: 10.1200/jco.2017.35.18_suppl.lba9007 – volume: 4 start-page: 1349 year: 2005 ident: BFnrc201784_CR133 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-05-0149 – volume: 376 start-page: 629 year: 2017 ident: BFnrc201784_CR16 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1612674 – volume: 12 start-page: S358 year: 2017 ident: BFnrc201784_CR136 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.398 – volume: 131 start-page: 1190 year: 2007 ident: BFnrc201784_CR273 publication-title: Cell doi: 10.1016/j.cell.2007.11.025 – volume: 22 start-page: 5527 year: 2016 ident: BFnrc201784_CR31 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0569 – volume: 8 start-page: e75 year: 2013 ident: BFnrc201784_CR199 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e318293d96f – volume: 7 start-page: 6653 year: 2014 ident: BFnrc201784_CR206 publication-title: Int. J. Clin. Exp. Pathol. – volume: 15 start-page: 460 year: 2009 ident: BFnrc201784_CR17 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-08-1757 – volume: 3 start-page: 75ra26 year: 2011 ident: BFnrc201784_CR78 publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3002003 – volume: 21 start-page: 4014 year: 2015 ident: BFnrc201784_CR230 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-0016 – volume: 7 start-page: e41017 year: 2012 ident: BFnrc201784_CR170 publication-title: PLoS ONE doi: 10.1371/journal.pone.0041017 – volume: 11 start-page: 759 year: 2013 ident: BFnrc201784_CR179 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-12-0652 – volume: 12 start-page: 833 year: 2017 ident: BFnrc201784_CR72 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2017.01.023 – volume: 11 start-page: 1273 year: 2016 ident: BFnrc201784_CR183 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.04.001 – volume: 10 start-page: 481 year: 2011 ident: BFnrc201784_CR141 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-10-0502 – volume: 5 start-page: 850 year: 2015 ident: BFnrc201784_CR61 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0285 – volume: 74 start-page: 1023 year: 2014 ident: BFnrc201784_CR257 publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-014-2578-6 – volume: 11 start-page: 535 year: 2016 ident: BFnrc201784_CR132 publication-title: Oncol. Lett. doi: 10.3892/ol.2015.3945 – volume: 22 start-page: 5983 year: 2016 ident: BFnrc201784_CR104 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0917 – volume: 22 start-page: 472 year: 2016 ident: BFnrc201784_CR7 publication-title: Nat. Med. doi: 10.1038/nm.4091 – volume: 70 start-page: 10038 year: 2010 ident: BFnrc201784_CR102 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-2956 – volume: 103 start-page: 1670 year: 2005 ident: BFnrc201784_CR175 publication-title: Cancer doi: 10.1002/cncr.20950 – volume: 29 start-page: 2046 year: 2011 ident: BFnrc201784_CR39 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.33.1280 – volume: 6 start-page: 36 year: 2016 ident: BFnrc201784_CR97 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0940 – volume: 29 start-page: e443 year: 2011 ident: BFnrc201784_CR255 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2010.34.1313 – volume: 371 start-page: 1963 year: 2014 ident: BFnrc201784_CR5 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1406766 – ident: BFnrc201784_CR256 – volume: 111 start-page: E748 year: 2014 ident: BFnrc201784_CR117 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1320956111 – volume: 10 start-page: 601 year: 2016 ident: BFnrc201784_CR200 publication-title: Mol. Oncol. doi: 10.1016/j.molonc.2015.11.007 – volume: 14 start-page: 1351 year: 2008 ident: BFnrc201784_CR297 publication-title: Nat. Med. doi: 10.1038/nm.1890 – volume: 4 start-page: 606 year: 2014 ident: BFnrc201784_CR119 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0741 – volume: 22 start-page: 1313 year: 2016 ident: BFnrc201784_CR156 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-1458 – volume: 150 start-page: 1107 year: 2012 ident: BFnrc201784_CR40 publication-title: Cell doi: 10.1016/j.cell.2012.08.029 – volume: 5 start-page: 960 year: 2015 ident: BFnrc201784_CR120 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-15-0063 – volume: 107 start-page: 1179 year: 2016 ident: BFnrc201784_CR286 publication-title: Cancer Sci. doi: 10.1111/cas.12996 – volume: 5 start-page: 7328 year: 2014 ident: BFnrc201784_CR207 publication-title: Oncotarget doi: 10.18632/oncotarget.2397 – volume: 10 start-page: 1187 year: 2015 ident: BFnrc201784_CR228 publication-title: Cell Rep. doi: 10.1016/j.celrep.2015.01.040 – volume: 15 start-page: 6630 year: 2009 ident: BFnrc201784_CR214 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-09-1001 – volume: 9 start-page: e86459 year: 2014 ident: BFnrc201784_CR223 publication-title: PLoS ONE doi: 10.1371/journal.pone.0086459 – ident: BFnrc201784_CR21 – volume: 77 start-page: 2712 year: 2017 ident: BFnrc201784_CR75 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-16-3404 – volume: 9 start-page: 5238 year: 2003 ident: BFnrc201784_CR171 publication-title: Clin. Cancer Res. – volume: 111 start-page: 8895 year: 2014 ident: BFnrc201784_CR58 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1404639111 – volume: 4 start-page: 120ra117 year: 2012 ident: BFnrc201784_CR93 publication-title: Sci. Transl Med. doi: 10.1126/scitranslmed.3003316 – volume: 35 start-page: 1403 year: 2017 ident: BFnrc201784_CR290 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.70.9352 – volume: 134 start-page: 1484 year: 2014 ident: BFnrc201784_CR262 publication-title: Int. J. Cancer doi: 10.1002/ijc.28475 – volume: 19 start-page: 1469 year: 2013 ident: BFnrc201784_CR283 publication-title: Nat. Med. doi: 10.1038/nm.3352 – volume: 21 start-page: 642 year: 2015 ident: BFnrc201784_CR212 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-14-0846 – volume: 5 start-page: 950 year: 2010 ident: BFnrc201784_CR249 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3181e2138b – ident: BFnrc201784_CR188 – volume: 14 start-page: 1019 year: 2016 ident: BFnrc201784_CR52 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-15-0506 – volume: 22 start-page: 5130 year: 2016 ident: BFnrc201784_CR254 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-0399 – volume: 26 start-page: 1421 year: 2015 ident: BFnrc201784_CR74 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv186 – volume: 20 start-page: 1027 year: 2014 ident: BFnrc201784_CR181 publication-title: Nat. Med. doi: 10.1038/nm.3667 – volume: 377 start-page: 829 year: 2017 ident: BFnrc201784_CR36 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1704795 – volume: 18 start-page: 1472 year: 2012 ident: BFnrc201784_CR101 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-2906 – volume: 84 start-page: 161 year: 2014 ident: BFnrc201784_CR313 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2014.02.011 – volume: 2 start-page: 127 year: 2001 ident: BFnrc201784_CR19 publication-title: Nat. Rev. Mol. Cell Biol. doi: 10.1038/35052073 – volume: 210 start-page: 2851 year: 2013 ident: BFnrc201784_CR215 publication-title: J. Exp. Med. doi: 10.1084/jem.20131195 – volume: 16 start-page: 229 year: 2014 ident: BFnrc201784_CR294 publication-title: J. Mol. Diagn. doi: 10.1016/j.jmoldx.2013.11.007 – volume: 108 start-page: 7535 year: 2011 ident: BFnrc201784_CR116 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1019559108 – volume: 19 start-page: 2013 year: 2007 ident: BFnrc201784_CR285 publication-title: Cell. Signal. doi: 10.1016/j.cellsig.2007.06.023 – volume: 4 start-page: 1046 year: 2014 ident: BFnrc201784_CR88 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-14-0337 – volume: 139 start-page: 379 year: 2013 ident: BFnrc201784_CR217 publication-title: J. Cancer Res. Clin. Oncol. doi: 10.1007/s00432-012-1328-6 – volume: 71 start-page: 5255 year: 2011 ident: BFnrc201784_CR301 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-10-4433 – volume: 11 start-page: 737 year: 2016 ident: BFnrc201784_CR316 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.01.022 – volume: 6 start-page: 6377 year: 2015 ident: BFnrc201784_CR198 publication-title: Nat. Commun. doi: 10.1038/ncomms7377 – volume: 4 start-page: 662 year: 2014 ident: BFnrc201784_CR29 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0846 – volume: 15 start-page: 19 year: 2004 ident: BFnrc201784_CR178 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdh031 – volume: 70 start-page: 399 year: 2012 ident: BFnrc201784_CR250 publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-012-1929-4 – volume: 10 start-page: e0121323 year: 2015 ident: BFnrc201784_CR1 publication-title: PLoS ONE doi: 10.1371/journal.pone.0121323 – volume: 7 start-page: 137 year: 2017 ident: BFnrc201784_CR28 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-16-1123 – volume: 6 start-page: 32258 year: 2016 ident: BFnrc201784_CR218 publication-title: Scientif. Rep. doi: 10.1038/srep32258 – volume: 17 start-page: 7394 year: 2011 ident: BFnrc201784_CR92 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-11-1648 – volume: 31 start-page: 1997 year: 2013 ident: BFnrc201784_CR70 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.45.6095 – volume: 5 start-page: 231 year: 2004 ident: BFnrc201784_CR176 publication-title: Clin. Lung Cancer doi: 10.3816/CLC.2004.n.004 – ident: BFnrc201784_CR26 doi: 10.1038/nature13385 – volume: 19 start-page: 1040 year: 2014 ident: BFnrc201784_CR148 publication-title: Oncologist doi: 10.1634/theoncologist.2014-0228 – volume: 141 start-page: 69 year: 2010 ident: BFnrc201784_CR209 publication-title: Cell doi: 10.1016/j.cell.2010.02.027 – volume: 35 start-page: 8026 year: 2014 ident: BFnrc201784_CR55 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8026 – volume: 7 start-page: 1807 year: 2012 ident: BFnrc201784_CR243 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182745948 – volume: 69 start-page: 3256 year: 2009 ident: BFnrc201784_CR129 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-08-4055 – volume: 83 start-page: 37 year: 2014 ident: BFnrc201784_CR168 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2013.09.019 – volume: 22 start-page: 3148 year: 2016 ident: BFnrc201784_CR298 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-2377 – volume: 75 start-page: 475 year: 2015 ident: BFnrc201784_CR314 publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-014-2664-9 – volume: 33 start-page: abstr. 2509 year: 2015 ident: BFnrc201784_CR302 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2015.33.15_suppl.2509 – volume: 471 start-page: 523 year: 2011 ident: BFnrc201784_CR9 publication-title: Nature doi: 10.1038/nature09870 – volume: 33 start-page: 1958 year: 2015 ident: BFnrc201784_CR18 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2014.58.1736 – volume: 20 start-page: 2001 year: 2014 ident: BFnrc201784_CR187 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2233 – volume: 23 start-page: 6071 year: 2004 ident: BFnrc201784_CR27 publication-title: Oncogene doi: 10.1038/sj.onc.1207813 – volume: 68 start-page: 68 year: 2013 ident: BFnrc201784_CR77 publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2012.11.007 – volume: 10 start-page: 156 year: 2015 ident: BFnrc201784_CR253 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000380 – volume: 10 start-page: e0118210 year: 2015 ident: BFnrc201784_CR48 publication-title: PLoS ONE doi: 10.1371/journal.pone.0118210 – volume: 27 start-page: 281 year: 2016 ident: BFnrc201784_CR73 publication-title: Ann. Oncol. doi: 10.1093/annonc/mdv573 – volume: 22 start-page: 262 year: 2016 ident: BFnrc201784_CR83 publication-title: Nat. Med. doi: 10.1038/nm.4040 – volume: 8 start-page: e82236 year: 2013 ident: BFnrc201784_CR164 publication-title: PLoS ONE doi: 10.1371/journal.pone.0082236 – volume: 25 start-page: 282 year: 2014 ident: BFnrc201784_CR169 publication-title: Cancer Cell doi: 10.1016/j.ccr.2014.02.025 – volume: 79 start-page: 923 year: 2017 ident: BFnrc201784_CR308 publication-title: Cancer Chemother. Pharmacol. doi: 10.1007/s00280-017-3283-z – volume: 3 start-page: 1355 year: 2013 ident: BFnrc201784_CR229 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-13-0310 – volume: 373 start-page: 726 year: 2015 ident: BFnrc201784_CR45 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1502309 – volume: 17 start-page: 1672 year: 2016 ident: BFnrc201784_CR239 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30532-0 – volume: 12 start-page: S1069 year: 2017 ident: BFnrc201784_CR306 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.11.1496 – volume: 27 start-page: 1667 year: 2009 ident: BFnrc201784_CR66 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2008.19.1635 – volume: 7 start-page: e23 year: 2012 ident: BFnrc201784_CR279 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0b013e3182629903 – volume: 361 start-page: 958 year: 2009 ident: BFnrc201784_CR14 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa0904554 – volume: 12 start-page: 447 year: 2012 ident: BFnrc201784_CR38 publication-title: Expert Rev. Anticancer Ther. doi: 10.1586/era.12.17 – volume: 141 start-page: 1503 year: 2011 ident: BFnrc201784_CR220 publication-title: J. Thorac. Cardiovasc. Surg. doi: 10.1016/j.jtcvs.2010.11.056 – volume: 7 start-page: 10690 year: 2016 ident: BFnrc201784_CR238 publication-title: Nat. Commun. doi: 10.1038/ncomms10690 – volume: 12 start-page: 15 year: 2017 ident: BFnrc201784_CR68 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.10.014 – volume: 11 start-page: 2027 year: 2016 ident: BFnrc201784_CR34 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.08.126 – volume: 20 start-page: 1698 year: 2014 ident: BFnrc201784_CR236 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-13-2482 – volume: 32 start-page: 8001 year: 2014 ident: BFnrc201784_CR69 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2014.32.15_suppl.8001 – volume: 2 start-page: 934 year: 2012 ident: BFnrc201784_CR121 publication-title: Cancer Discov. doi: 10.1158/2159-8290.CD-12-0103 – volume: 10 start-page: 1736 year: 2015 ident: BFnrc201784_CR115 publication-title: J. Thorac. Oncol. doi: 10.1097/JTO.0000000000000688 – volume: 376 start-page: 2109 year: 2017 ident: BFnrc201784_CR232 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1616288 – volume: 11 start-page: S152 year: 2016 ident: BFnrc201784_CR241 publication-title: J. Thorac. Oncol. doi: 10.1016/S1556-0864(16)30324-0 – ident: BFnrc201784_CR246 – volume: 28 start-page: 565 year: 2017 ident: BFnrc201784_CR261 publication-title: Anticancer Drugs doi: 10.1097/CAD.0000000000000489 – volume: 7 start-page: 1824 year: 2014 ident: BFnrc201784_CR135 publication-title: Cell Rep. doi: 10.1016/j.celrep.2014.05.039 – volume: 97 start-page: 339 year: 2005 ident: BFnrc201784_CR287 publication-title: J. Natl Cancer Inst. doi: 10.1093/jnci/dji055 – volume: 22 start-page: 4585 year: 2016 ident: BFnrc201784_CR231 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-15-3101 – volume: 101 start-page: 1279 year: 2010 ident: BFnrc201784_CR191 publication-title: Cancer Sci. doi: 10.1111/j.1349-7006.2010.01511.x – volume: 34 start-page: 108 year: 2016 ident: BFnrc201784_CR64 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2016.34.15_suppl.108 – volume: 58 start-page: 9 year: 2017 ident: BFnrc201784_CR216 publication-title: Yonsei Med. J. doi: 10.3349/ymj.2017.58.1.9 – volume: 18 start-page: 378 year: 2012 ident: BFnrc201784_CR278 publication-title: Nat. Med. doi: 10.1038/nm.2658 – volume: 13 start-page: 2910 year: 2014 ident: BFnrc201784_CR295 publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-14-0274 – volume: 120 start-page: 3896 year: 2014 ident: BFnrc201784_CR235 publication-title: Cancer doi: 10.1002/cncr.28964 – volume: 21 start-page: 1038 year: 2015 ident: BFnrc201784_CR124 publication-title: Nat. Med. doi: 10.1038/nm.3930 – volume: 431 start-page: 525 year: 2004 ident: BFnrc201784_CR270 publication-title: Nature doi: 10.1038/431525b – volume: 18 start-page: 6219 year: 2012 ident: BFnrc201784_CR173 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-12-0392 – volume: 23 start-page: 4929 year: 2017 ident: BFnrc201784_CR110 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-16-3273 – volume: 4 start-page: 33 year: 2015 ident: BFnrc201784_CR245 publication-title: Chin. Clin. Oncol. – volume: 17 start-page: 1661 year: 2016 ident: BFnrc201784_CR309 publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(16)30561-7 – volume: 108 start-page: 53 year: 2017 ident: BFnrc201784_CR167 publication-title: Cancer Sci. doi: 10.1111/cas.13111 – volume: 8 start-page: 995 year: 2001 ident: BFnrc201784_CR63 publication-title: Mol. Cell doi: 10.1016/S1097-2765(01)00378-1 – volume: 352 start-page: 786 year: 2005 ident: BFnrc201784_CR81 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa044238 – volume: 29 start-page: 3574 year: 2011 ident: BFnrc201784_CR41 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.35.9638 – ident: BFnrc201784_CR159 – volume: 8 start-page: 809 year: 2010 ident: BFnrc201784_CR213 publication-title: Mol. Cancer Res. doi: 10.1158/1541-7786.MCR-09-0460 – volume: 12 start-page: 102 year: 2017 ident: BFnrc201784_CR143 publication-title: J. Thorac. Oncol. doi: 10.1016/j.jtho.2016.08.140 – volume: 113 start-page: E1419 year: 2016 ident: BFnrc201784_CR35 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.1522052113 – volume: 9 start-page: 601 year: 1999 ident: BFnrc201784_CR189 publication-title: Curr. Biol. doi: 10.1016/S0960-9822(99)80265-6 – volume: 4 start-page: e294 year: 2007 ident: BFnrc201784_CR184 publication-title: PLoS Med. doi: 10.1371/journal.pmed.0040294 – volume: 31 start-page: 8116 year: 2013 ident: BFnrc201784_CR259 publication-title: J. Clin. Oncol. doi: 10.1200/jco.2013.31.15_suppl.8116 – volume: 8 start-page: 3665 year: 2015 ident: BFnrc201784_CR211 publication-title: Onco Targets Ther. doi: 10.2147/OTT.S89659 – volume: 14 start-page: 4877 year: 2008 ident: BFnrc201784_CR8 publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-5123 – volume: 374 start-page: 54 year: 2016 ident: BFnrc201784_CR114 publication-title: N. Engl. J. Med. doi: 10.1056/NEJMoa1508887 – volume: 17 start-page: 281 year: 2017 ident: BFnrc201784_CR100 publication-title: BMC Cancer doi: 10.1186/s12885-017-3263-z – volume: 11 start-page: 1444 year: 2009 ident: BFnrc201784_CR194 publication-title: Nat. Cell Biol. doi: 10.1038/ncb1993 – volume: 42 start-page: 581 year: 1985 ident: BFnrc201784_CR265 publication-title: Cell doi: 10.1016/0092-8674(85)90115-1 – volume: 534 start-page: 647 year: 2016 ident: BFnrc201784_CR51 publication-title: Nature doi: 10.1038/nature18600 – volume: 47 start-page: 250 year: 2015 ident: BFnrc201784_CR53 publication-title: Nat. Genet. doi: 10.1038/ng.3218 – volume: 123 start-page: 2927 year: 2017 ident: BFnrc201784_CR185 publication-title: Cancer doi: 10.1002/cncr.30677 – volume: 45 start-page: 1430 year: 2014 ident: BFnrc201784_CR225 publication-title: Int. J. Oncol. doi: 10.3892/ijo.2014.2574 – volume: 31 start-page: 3327 year: 2013 ident: BFnrc201784_CR15 publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2012.44.2806 – volume: 108 start-page: 228 year: 2017 ident: BFnrc201784_CR91 publication-title: Lung Cancer doi: 10.1016/j.lungcan.2017.04.003 – volume: 105 start-page: 2070 year: 2008 ident: BFnrc201784_CR82 publication-title: Proc. Natl Acad. Sci. USA doi: 10.1073/pnas.0709662105 – volume: 66 start-page: 944 year: 2006 ident: BFnrc201784_CR202 publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-1988 – volume: 131 start-page: E227 year: 2012 ident: BFnrc201784_CR227 publication-title: Int. J. Cancer doi: 10.1002/ijc.27403 – volume: 474 start-page: 154 year: 2016 ident: BFnrc201784_CR192 publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2016.04.089
SSID	ssj0016171
Score	2.6917653
SecondaryResourceType	review_article
Snippet	Key Points The spectrum of known and putative oncogenic drivers with companion targeted therapies continues to increase. As broader mutational testing becomes... The expanding spectrum of both established and candidate oncogenic driver mutations identified in non-small-cell lung cancer (NSCLC), coupled with the...
SourceID	proquest gale pubmed crossref springer
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	637
SubjectTerms	631/67/1059/2326 631/67/1059/602 631/67/1612/1350 AKT protein Animals Antineoplastic Agents - pharmacology Biomedicine Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Drug Resistance, Neoplasm - drug effects Epidermal growth factor Epidermal growth factor receptors Genetic aspects Humans Kinases Lung Neoplasms - drug therapy Lung Neoplasms - pathology Lymphoma Microbial drug resistance Mutation Non-small cell lung cancer Non-small cell lung carcinoma Protein-tyrosine kinase receptors Raf protein review-article Risk factors Signal transduction Threonine Tumor microenvironment Tumors
Title	Understanding and targeting resistance mechanisms in NSCLC
URI	https://link.springer.com/article/10.1038/nrc.2017.84 https://www.ncbi.nlm.nih.gov/pubmed/29068003 https://www.proquest.com/docview/1955646694 https://www.proquest.com/docview/1955617679
Volume	17
WOSCitedRecordID	wos000413667100005&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: M7P dateStart: 20011001 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: M0R dateStart: 20011001 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: 7X7 dateStart: 20011001 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: 7RV dateStart: 20011001 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: BENPR dateStart: 20011001 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database (ProQuest) customDbUrl: eissn: 1474-1768 dateEnd: 20171231 omitProxy: false ssIdentifier: ssj0016171 issn: 1474-175X databaseCode: 8C1 dateStart: 20011001 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpR1db9Mw8MQ2hPbC-F5gjCANISGFJbHjD17QqDbxwKpqMNQ3y7UdqRJLR9Pt98_nuFk7EC-8OIp8Sezcne_s-wI4cNZLRctJ5lVhk9GJyzPJnMy0lBoToKPlLBSb4MOhGI_lKB64tdGtcrkmhoXazgyekR8WsqoYZUzSz5e_M6wahdbVWEJjA7YwSwIJrnuj3orgpXPYcFFOMy8mxzE-LyfisJlj_sKCfxR0TSLdXZdXBNMdS2kQQCc7_zv0R_Awqp7pUUcrj-Gea57Ag9NoXH8Kn85XA11Sf0k7P3G887ty1DQ9iaQXDqOFp-1Fm06bdPh98G3wDM5Pjn8MvmaxtEJmaFUuMNZKalHWtWCidtYWRmtTSktszarS5BOvJpQ1q3PtiNOeSblEWa4rqjUpJxPyHDabWeN2IS2s0IZaykitqSu0zBHFNSbSR0_FPIEPy9-rTMw7juUvfqlg_yZCeVwoxIUSNIGDHviyS7fxd7A3iCfVxYr2TKqOUH0UuIdK4H2AQDb1XzM6Rhv4MWPCqzXIvTVIz15mvXuJVBXZu1W3GE3gbd-NT6LLWuNmVxGm4IzLBF50NNRPCXPse02dJPBuSVQrL_9zvi__PYhXsI2AXYjkHmwu5lfuNdw314tpO9-HDX72E9sxD63wrRgU-7D15Xg4OvN3p3lo-egGGtAXJg
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LT9wwEB5RqEovpU-aQksqgSpVSklix7GREEJbEIhlVbVQ7c312o60UsnSzdKKP8VvxJMXu7TqjQOnKMrYsePPM-PMC2DdGicVTUoCpwrrgA5sGAhmRaCEUJgAHS1nZbGJtNfj_b74MgdXTSwMulU2PLFk1Gak8R_5ZiSShFHGBN05_xVg1Si0rjYlNCpYHNnLP-7IVmwffnbruxHH-3snnYOgrioQaJrEEwwzEorHWcYZz6wxkVZKx8IQk7Ek1uHAScg4Y1moLLHK4TMVKMZUQpUi8WBAXL8PYMHx8QhdyNKv31urhdMGygMeTWngxHK_jgcMCd_Mx5gvMUo_cTojAW_LgSlBeMsyWwq8_aX79qmewpNatfZ3q73wDOZs_hweHdfOAy9g63Q6kMd3F7_yg8e7sS1Qk3ZbwD-zGA09LM4Kf5j7vW-dbuclnN7JyF_BfD7K7WvwI8OVpoYykilqIyVChHCGhQLQEzP04GOznFLXedWxvMdPWdr3CZdu7SWuveTUg_WW-LxKJ_JvsjXEhaxiYVsmJHdRPeZ4RvTgQ0mBbMi9Tas6msKNGRN6zVCuzlA69qFnHzcgkjX7KuQNgjx43z7GluiSl9vRRU0TpSwVHixXmG2nhDUE3EmEeLDRgHiq87_n--b_g1iDxYOT467sHvaOVuAxNqrCQVdhfjK-sG_hof49GRbjd-V-9OHHXaP6GpJ_b18
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3fa9swED66bpS97PdWb93qQctg4MW2ZFkqlFLShZV2obAV8qYqsgSB1unidGP_2v666WzZTbqxtz7syRifZdn6dKez7rsD2DKFs4pFTiK3FNYRHZs4EsyISAmhMAE67pzVxSby4ZCPRuJkBX61XBgMq2x1Yq2oi6nGf-S9RGQZo4wJ2rM-LOLkYLB3-S3CClK409qW02ggcmR-_nDuW7V7eODGejtNBx-_9j9FvsJApGmWzpFyJBRPreWMW1MUiVZKp6IghWVZquOxs5apZTZWhhjlsJoLNGkqo0qRdDwmrt07cDcnDsXIUu934SXoNtTOHs1p5Ez0yHMDY8J75QxzJyb5B06XrOFNm7BgFG_s0tbGb_Dwf_5sj-CBX3KH-80ceQwrpnwCa599UMFT2DldJPiE7hA28fF4NjMVrrDd1AgvDLKkJ9VFFU7KcPilf9x_Bqe30vPnsFpOS7MOYVJwpWlBGbGKmkSJGKFtsYAARmjGAbxvh1Zqn28dy36cy3rfn3DpcCARB5LTALY64csmzcjfxTYRI7LhyHbKSe7jspmj7xjAu1oC1ZN7mlaeZeH6jIm-liQ3liSdWtHLl1tASa_WKnmNpgDedpfxTgzVK830ysskOctFAC8a_HavhLUFnIdCAthuAb3Q-J_v-_LfndiENQdmeXw4PHoF9_GehiW6Aavz2ZV5Dff09_mkmr2pp2YIZ7cN6t_h0He6
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Understanding+and+targeting+resistance+mechanisms+in+NSCLC&rft.jtitle=Nature+reviews.+Cancer&rft.au=Rotow%2C+Julia&rft.au=Bivona%2C+Trever+G&rft.date=2017-11-01&rft.issn=1474-1768&rft.eissn=1474-1768&rft.volume=17&rft.issue=11&rft.spage=637&rft_id=info:doi/10.1038%2Fnrc.2017.84&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1474-175X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1474-175X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1474-175X&client=summon